[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 980
1. Kim L, Liao J, Zhang M, Talamonti M, Bentrem D, Rao S, Yang GY: Clear cell carcinoma of the pancreas: histopathologic features and a unique biomarker: hepatocyte nuclear factor-1beta. Mod Pathol; 2008 Sep;21(9):1075-83
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma of the pancreas: histopathologic features and a unique biomarker: hepatocyte nuclear factor-1beta.
  • Clear cell carcinoma as a variant of ductal carcinoma of the pancreas is not well recognized.
  • Hepatocyte nuclear factor-1beta as a transcription factor has been identified as a specific biomarker of clear cell tumor of the female genital tract.
  • The aim of this study was to systematically analyze clear cell carcinoma of the pancreas and its unique biomarker hepatocyte nuclear factor-1beta.
  • A total of 84 pancreatic adenocarcinomas were analyzed pathologically and with an immunohistochemical approach with hepatocyte nuclear factor-1beta antibody.
  • The identified clear cell carcinomas were further studied by PAS, DPAS, and mucicarmine stains.
  • Of them, 20 (24%) pancreatic adenocarcinomas were identified with clear cell features, including 12 clear cell carcinomas and 8 ductal adenocarcinomas with clear cell component (defined as less than 75% of tumor with clear cells).
  • Cytologically, the clear cell carcinomas exhibited clear cytoplasm with centrally located, atypical nuclei.
  • PAS, DPAS, and mucicarmine stains confirmed that the clear cytoplasm was not due to accumulation of glycogen or mucin.
  • The results of immunostaining showed that hepatocyte nuclear factor-1beta is overexpressed in all clear cell carcinomas and in the clear cell components of eight ductal carcinomas with clear cell features.
  • In contrast, in usual ductal adenocarcinoma, hepatocyte nuclear factor-1beta exhibited overall weak or focally moderate staining; only eight cases were strongly positive (15%) of which 38% were high grade and 63% were moderate grade.
  • However, when included with the strong staining cases in mixed and clear cell carcinoma, this group regardless of morphology appeared to correlate with worse survival compared to the group with weak hepatocyte nuclear factor-1beta staining across morphologies (P<0.01).
  • Thus, clear cell carcinoma of the pancreas is not an uncommon variant of pancreatic ductal adenocarcinoma.
  • Hepatocyte nuclear factor-1beta is a useful marker to identify these clear cell carcinomas, and its overexpression may aid in stratifying survival rate.
  • [MeSH-major] Adenocarcinoma, Clear Cell / chemistry. Adenocarcinoma, Clear Cell / pathology. Biomarkers, Tumor / analysis. Hepatocyte Nuclear Factor 1-beta / analysis. Pancreatic Neoplasms / chemistry. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Pancreatic Ductal / chemistry. Carcinoma, Pancreatic Ductal / pathology. Cell Nucleus / metabolism. Cell Nucleus / pathology. Fluorescent Antibody Technique, Direct. Humans. Immunoenzyme Techniques. Immunohistochemistry. Neoplasm Staging. Periodic Acid-Schiff Reaction

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18536653.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 138674-15-4 / Hepatocyte Nuclear Factor 1-beta
  •  go-up   go-down


2. Yamamoto S, Tsuda H, Takano M, Kita T, Kudoh K, Furuya K, Tamai S, Matsubara O: Expression of platelet-derived growth factors and their receptors in ovarian clear-cell carcinoma and its putative precursors. Mod Pathol; 2008 Feb;21(2):115-24
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of platelet-derived growth factors and their receptors in ovarian clear-cell carcinoma and its putative precursors.
  • Herein, we investigated the role of the platelet-derived growth factor pathway in the development of ovarian clear-cell adenocarcinoma, a highly chemoresistant form of ovarian cancer.
  • Immunohistochemical expression of platelet-derived growth factor receptor-alpha and receptor-beta, platelet-derived growth factor A-chain and B-chain was examined in 31 cases of clear-cell adenocarcinoma and 56 coexisting putative precursor lesions: 17 non-atypical and 19 atypical endometrioses, and 10 non-atypical and 10 atypical clear-cell adenofibroma components.
  • The frequencies of positivity for platelet-derived growth factor receptor-alpha and receptor-beta, and platelet-derived growth factor A-chain increased in accordance with higher cytologic atypia in the putative precursors: 71, 47, and 59% in the 17 non-atypical endometrioses, 84, 73, and 84% in the 19 atypical endometrioses, 0% each in the 10 non-atypical clear-cell adenofibromas, 100, 90, and 90% in the 10 atypical clear-cell adenofibromas, and 97, 97, and 100% in the 31 clear-cell adenocarcinomas, respectively.
  • Positivity for platelet-derived growth factor B-chain increased in accordance with increased atypia in clear-cell adenofibroma: 0% in non-atypical clear-cell adenofibromas, 30% in atypical clear-cell adenofibromas, and 60% in coexisting carcinomas.
  • However, in contrast, positivity for platelet-derived growth factor B-chain decreased in accordance with increased atypia in endometriosis coexisting with clear-cell adenocarcinomas: 35% in non-atypical endometrioses, 11% in atypical endometrioses, and 5% in coexisting carcinomas.
  • These results indicate activation of the platelet-derived growth factor pathway in ovarian clear-cell adenocarcinomas and suggest biological differences between carcinomas that arise in association with clear-cell adenofibroma vs endometriosis.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Adenofibroma / metabolism. Endometriosis / metabolism. Ovarian Neoplasms / metabolism. Platelet-Derived Growth Factor / metabolism. Receptors, Platelet-Derived Growth Factor / metabolism

  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18084257.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Platelet-Derived Growth Factor; EC 2.7.10.1 / Receptors, Platelet-Derived Growth Factor
  •  go-up   go-down


3. Terada T, Kawaguchi M: Primary clear cell adenocarcinoma of the peritoneum. Tohoku J Exp Med; 2005 Jul;206(3):271-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary clear cell adenocarcinoma of the peritoneum.
  • We report on a very rare case of peritoneal clear cell adenocarcinomas.
  • A 49-year-old Japanese woman underwent hysterectomy and bilateral salpingo-oophorectomy for endometrial endometrioid adenocarcinoma grade III, which was composed of undifferentiated carcinoma cells (98%) and tubular carcinoma cells (2%).
  • No clear cell adenocarcinoma elements were noted in this tumor.
  • Two peritoneal cystic tumors were detected by imaging modalities around the stomach and spleen, 15 months and 21 months after the follow-up period of the endometrial carcinoma, respectively.
  • They showed proliferation of carcinoma cells arranged in solid nest, tubular, and papillary patterns.
  • They showed clear cytoplasm positive for periodic acid-Schiff stain, hobnail cells, and occasional hyaline globules.
  • The morphologies fulfilled the criteria of clear cell adenocarcinoma.
  • The morphologies and immunohistochemical findings of the two peritoneal clear cell adenocarcinomas were different from those of endometrial carcinoma.
  • We believe that the two clear cell adenocarcinomas are not metastatic lesions from the endometrial carcinoma of the uterus, and that they are primary clear cell adenocarcinomas of the peritoneum.
  • Our case was characterized by cyst formations and encapsulation in addition to the common histological features of clear cell adenocarcinoma of the uterus and ovary.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Peritoneal Neoplasms / diagnosis
  • [MeSH-minor] Cell Proliferation. Cytoplasm / metabolism. Endometrial Neoplasms / metabolism. Female. Humans. Hysterectomy. Immunohistochemistry. Middle Aged. Ovary / pathology. Periodic Acid-Schiff Reaction. Spleen / metabolism. Stomach / metabolism. Uterine Neoplasms. Uterus / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15942157.001).
  • [ISSN] 0040-8727
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


Advertisement
4. Maeda D, Ota S, Takazawa Y, Aburatani H, Nakagawa S, Yano T, Taketani Y, Kodama T, Fukayama M: Glypican-3 expression in clear cell adenocarcinoma of the ovary. Mod Pathol; 2009 Jun;22(6):824-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glypican-3 expression in clear cell adenocarcinoma of the ovary.
  • Glypican-3 is a heparan sulfate proteoglycan that is overexpressed in various neoplasms such as hepatocellular carcinoma, malignant melanoma, and testicular yolk sac tumor.
  • To clarify the significance of glypican-3 expression in ovarian clear cell adenocarcinoma, we evaluated glypican-3 expression by immunohistochemistry in nonneoplastic and neoplastic ovaries, and other Müllerian duct derivatives including endometrium in different menstrual phases.
  • A total of 213 cases of ovarian adenocarcinoma, including 94 clear cell adenocarcinomas, were studied.
  • Glypican-3 expression was observed in 44% of clear cell adenocarcinomas, whereas it was rarely observed in other histological subtypes: mucinous (4%), endometrioid (5%), and serous (11%; P<0.0001).
  • In cases of clear cell adenocarcinoma, no correlations were found between glypican-3 expression and clinicopathological factors, such as tumor stage, lymph node metastasis, peritoneal dissemination, and death rate.
  • However, glypican-3 expression was significantly associated with poor overall survival in stage III/IV clear cell adenocarcinoma cases.
  • Our results suggest that overexpression of glypican-3 may be related to the development and aggressive behavior of ovarian clear cell adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Biomarkers, Tumor / analysis. Glypicans / biosynthesis. Ovarian Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19329941.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glypicans
  •  go-up   go-down


5. Nishimura S, Tsuda H, Ito K, Jobo T, Yaegashi N, Inoue T, Sudo T, Berkowitz RS, Mok SC: Differential expression of ABCF2 protein among different histologic types of epithelial ovarian cancer and in clear cell adenocarcinomas of different organs. Hum Pathol; 2007 Jan;38(1):134-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of ABCF2 protein among different histologic types of epithelial ovarian cancer and in clear cell adenocarcinomas of different organs.
  • Previously, we reported that ABCF2 protein expression is higher in clear cell than serous histotype of ovarian adenocarcinomas and that its expression correlates with chemoresponse in patients with clear cell ovarian cancer.
  • In this study, we examined ABCF2 protein expression in mucinous, endometrioid, and poorly differentiated type of ovarian adenocarcinomas.
  • In addition, ABCF2 expression was evaluated in clear cell adenocarcinomas derived from different organs.
  • A total of 335 epithelial ovarian cancers, 23 clear cell adenocarcinomas of uterine corpus, and 34 clear cell adenocarcinomas of kidney were included in this study.
  • The results showed that cytoplasmic ABCF2 expression was significantly higher in clear cell-type ovarian cancer specimens compared with other types (P < .0001).
  • There was a close relationship between nuclear ABCF2 expression levels and age of patients with clear cell ovarian cancer.
  • Multivariate logistic regression model also demonstrated that cytoplasmic ABCF2 expression was associated with clear cell histology (odds ratio, 5.557; 95% confidence interval, 2.694-11.462; P < .0001).
  • In addition, both clear cell adenocarcinomas of the ovary and the uterine corpus showed significantly higher levels of ABCF2 expression, compared with those of the clear cell adenocarcinoma of the kidney (P < .0001).
  • These data suggest that ABCF2 protein may be a candidate marker for clear cell adenocarcinomas of the ovary and the uterine corpus and may be important for the pathogenesis of these diseases.
  • [MeSH-major] ATP-Binding Cassette Transporters / biosynthesis. Adenocarcinoma, Clear Cell / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Epithelial Cells / chemistry. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry. Logistic Models. Middle Aged. Multivariate Analysis. Odds Ratio

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16996567.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50CA165009; United States / NCI NIH HHS / CA / R33CA103595
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCF2 protein, human
  •  go-up   go-down


6. Uddin Z, Yaqoob N, Kayani N, Hasan SH: Clear cell carcinoma of ovary with associated mucinous cystadenoma and endometriosis. J Pak Med Assoc; 2007 Jul;57(7):373-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma of ovary with associated mucinous cystadenoma and endometriosis.
  • Histological picture showed clear cell carcinoma with areas of mucinous cystadenoma and endometriosis.
  • Clear cell carcinoma is known to be associated with endometriosis.
  • To the best of author's knowledge, it's association with mucinous cystadenoma has been described only once in the literature, where clear cell carcinoma was shown to be associated with mucinous cystadenoma without any evidence of endometriosis.
  • [MeSH-major] Adenocarcinoma, Clear Cell / etiology. Cystadenoma, Mucinous / complications. Endometriosis / complications. Ovarian Neoplasms / etiology

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17867264.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


7. Ponniah I, SureshKumar P, Karunakaran K: Clear cell carcinoma of minor salivary gland--case report. Ann Acad Med Singapore; 2007 Oct;36(10):857-60
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma of minor salivary gland--case report.
  • INTRODUCTION: Clear cell carcinoma is a rare low-grade carcinoma that almost exclusively occurs in the minor salivary glands.
  • TREATMENT AND OUTCOME: A preoperative diagnosis of primary clear cell carcinoma of salivary gland with focal surface epithelial dysplasia was rendered after thorough clinical examination to rule out renal origin.
  • The lesions were excised with wide surgical margins and 3 years into the postoperative period, the patient was disease-free.
  • CONCLUSION: We report a case of clear cell carcinoma of intra-oral minor salivary gland and draw comparisons with metastatic clear cell carcinoma of renal origin.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Salivary Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17987239.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


8. Sung MT, Zhang S, MacLennan GT, Lopez-Beltran A, Montironi R, Wang M, Tan PH, Cheng L: Histogenesis of clear cell adenocarcinoma in the urinary tract: evidence of urothelial origin. Clin Cancer Res; 2008 Apr 1;14(7):1947-55
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histogenesis of clear cell adenocarcinoma in the urinary tract: evidence of urothelial origin.
  • PURPOSE: Clear cell adenocarcinoma in the urinary tract is a rare entity with an appearance resembling its counterpart in the female genital tract.
  • EXPERIMENTAL DESIGN: We integrated molecular genetic evaluation by fluorescence in situ hybridization and X-chromosome inactivation with conventional morphologic and immunohistochemical analyses in 12 patients with clear cell adenocarcinomas in the urinary tract.
  • RESULTS: Concurrent urothelial carcinoma or urothelial carcinoma in situ was present in six cases (50%) and foci of cystitis glandularis were observed in four cases (33%).
  • In UroVysion fluorescence in situ hybridization assays, all tumors displayed chromosomal alterations similar to those commonly found in urothelial carcinoma.
  • Identical patterns of nonrandom X-chromosome inactivation in concurrent clear cell adenocarcinoma and urothelial neoplasia were identified in two informative female cases.
  • CONCLUSIONS: Our findings support an urothelial origin for most clear cell adenocarcinomas of the urinary tract, despite their morphologic resemblance to certain Müllerian-derived tumors of the female genital tract.
  • [MeSH-major] Adenocarcinoma, Clear Cell / genetics. Biomarkers, Tumor / analysis. Urologic Neoplasms / genetics. Urologic Neoplasms / metabolism. Urothelium / pathology
  • [MeSH-minor] Adult. Aged. Carcinoma, Transitional Cell / genetics. Carcinoma, Transitional Cell / metabolism. Carcinoma, Transitional Cell / pathology. Female. Gene Expression. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. X Chromosome Inactivation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18381932.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


9. Akbulut M, Zekioglu O, Terek MC, Ozdemir N: Chondromatous differentiation in clear cell carcinoma of the ovary: a rare finding challenging the differential diagnosis. Arch Gynecol Obstet; 2008 Dec;278(6):569-72
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chondromatous differentiation in clear cell carcinoma of the ovary: a rare finding challenging the differential diagnosis.
  • OBJECTIVE: Ovarian surface epithelial tumors rarely have heterologous elements including bone or cartilage that may appear histologically benign or malignant.
  • CASE: We report a clear cell carcinoma of the bilateral ovary showing chondromatous differentiation in a 56-year-old woman.
  • Histopathologic study of the specimen showed clear cell carcinoma with many small foci of chondromatous differentiation.
  • Immunohistochemical studies demonstrated positivity for S-100 confirming the diagnosis.
  • The patient was alive with disease on chemotherapy for 16 months.
  • CONCLUSION: A rare case of benign appearing chondromatous differentiation in an ovarian clear cell carcinoma of the ovary is described, and the significance of this finding is discussed.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Chondroma / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Cell Differentiation / physiology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18343935.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


10. Yamamoto S, Tsuda H, Aida S, Shimazaki H, Tamai S, Matsubara O: Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium. Hum Pathol; 2007 Jul;38(7):1074-80
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium.
  • Recent studies have noted specific expression of hepatocyte nuclear factor (HNF) 1beta in ovarian clear-cell adenocarcinoma (CCA).
  • We examined HNF-1beta expression immunohistochemically in 186 ovarian carcinomas, including 40 CCAs; 33 endometrial carcinomas, including 5 CCAs; 22 endometria at different stages of the menstrual cycle (5 in the proliferative, 12 in the secretory, and 5 in the menstrual phases); and 7 gestational endometria.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Hepatocyte Nuclear Factor 1-beta / metabolism. Ovarian Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17442376.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 138674-15-4 / Hepatocyte Nuclear Factor 1-beta
  •  go-up   go-down


11. Nishimura S, Tsuda H, Ito K, Takano M, Terai Y, Jobo T, Kigawa J, Sugiyama T, Yaegashi N, Aoki D: Differential expression of hypoxia-inducible protein 2 among different histological types of epithelial ovarian cancer and in clear cell adenocarcinomas. Int J Gynecol Cancer; 2010 Feb;20(2):220-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of hypoxia-inducible protein 2 among different histological types of epithelial ovarian cancer and in clear cell adenocarcinomas.
  • Among them, clear cell adenocarcinoma (CCC) has a poor response to chemotherapy and poor prognosis compared with other histological types.
  • Cytoplasmic HIG2 expression is significantly more frequent in ovarian CCC (83.1%) than in serous (54.9%, P = 0.0001), mucinous (40%, P = 0.00002), or endometrioid (58.1%, P = 0.003) adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Biomarkers, Tumor / metabolism. Neoplasm Proteins / metabolism. Ovarian Neoplasms / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20134266.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HIG2 protein, human; 0 / Neoplasm Proteins
  •  go-up   go-down


12. Herawi M, Drew PA, Pan CC, Epstein JI: Clear cell adenocarcinoma of the bladder and urethra: cases diffusely mimicking nephrogenic adenoma. Hum Pathol; 2010 Apr;41(4):594-601
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell adenocarcinoma of the bladder and urethra: cases diffusely mimicking nephrogenic adenoma.
  • Although clear cell adenocarcinoma have been described focally mimicking nephrogenic adenoma, we have identified a subset of clear cell adenocarcinoma that diffusely resembles nephrogenic adenoma (nephrogenic adenoma-like clear cell adenocarcinoma).
  • Twelve classic clear cell adenocarcinomas of the bladder and urethra and 7 nephrogenic adenoma-like clear cell adenocarcinomas were compared to 10 nephrogenic adenomas.
  • Classic clear cell adenocarcinomas and nephrogenic adenoma-like clear cell adenocarcinomas comprised 4 men and 15 women.
  • The following features were seen in classic clear cell adenocarcinomas: nephrogenic adenoma-like clear cell adenocarcinomas: predominantly solid pattern (7/12:0/7), marked nuclear pleomorphism (7/12:1/7), prominent nucleoli (5/12:1/7), clear cytoplasm in 50% or greater of tumor (7/12:0/7), and necrosis (8/12:3/7), although the necrosis in nephrogenic adenoma-like clear cell adenocarcinomas was often focal and intraluminal.
  • Both patterns of clear cell adenocarcinomas showed prominent hobnail features, although more pronounced in nephrogenic adenoma-like clear cell adenocarcinomas.
  • Muscularis propria invasion was seen in 5 of 9 classic clear cell adenocarcinomas and 6 of 6 nephrogenic adenoma-like clear cell adenocarcinomas, where evaluable.
  • Classic clear cell adenocarcinoma was associated with urothelial carcinoma (n = 2) and endometriosis (n = 1).
  • The Ki-67 rate in clear cell adenocarcinomas ranged from 10% to 80% compared with 0% to 5% in nephrogenic adenoma.
  • The following antibodies were not helpful in distinguishing nephrogenic adenoma-like clear cell adenocarcinoma from nephrogenic adenoma: CD10, estrogen receptor, p63, high-molecular-weight cytokeratin, and alpha-methylacyl coenzyme-A racemase.
  • PAX2 expression was more frequent in nephrogenic adenoma (89%) compared to both patterns of clear cell adenocarcinoma (29%-32%).
  • The key features discriminating between nephrogenic adenoma-like clear cell adenocarcinoma and nephrogenic adenoma include occasional clear cells, more prominent pleomorphism especially hyperchromatic enlarged nuclei, and extensive muscular invasion.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Adenoma / diagnosis. Urethral Neoplasms / diagnosis. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Urothelium / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc.
  • (PMID = 20060152.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Adams B, Sawhney R, Sheil A, Chaudhary UB: A rare case of clear cell adenocarcinoma of the bladder with unique pathological features. Am J Med Sci; 2007 Jan;333(1):63-5
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of clear cell adenocarcinoma of the bladder with unique pathological features.
  • Clear cell adenocarcinomas of the urinary bladder are rare tumors with an unknown histogenesis.
  • Since these tumors appear histologically similar to clear cell tumors of the female genital tract, a mullerian histogenesis has been proposed.
  • Several publications have examined the immunohistochemical properties of clear cell adenocarcinomas to improve understanding of the cause and pathogenesis of this tumor.
  • While specific criteria for a diagnosis of clear cell adenocarcinoma have not been defined, there are consistent staining patterns suggested for characterization.
  • We present an important case of clear cell adenocarcinoma of the bladder with a unique staining pattern.
  • We review the literature and discuss the differential diagnosis and various theories concerning the origin of this rare tumor.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17220697.001).
  • [ISSN] 0002-9629
  • [Journal-full-title] The American journal of the medical sciences
  • [ISO-abbreviation] Am. J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


14. Hashiguchi Y, Tsuda H, Inoue T, Berkowitz RS, Mok SC: PTEN expression in clear cell adenocarcinoma of the ovary. Gynecol Oncol; 2006 Apr;101(1):71-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PTEN expression in clear cell adenocarcinoma of the ovary.
  • OBJECTIVES: In this study, we analyzed the PTEN expression in a large collection of clear cell adenocarcinomas of the ovary.
  • METHODS: Totally, 40 clear cell adenocarcinomas were included in this study.
  • RESULTS: Of 40 clear cell adenocarcinomas, 15 (37.5%) lost all PTEN immunoreactivity.
  • Cyclin D1 expression and loss of p27 expression were detected in 16/40 (40.0%) and 14/40 (35.0%) clear cell adenocarcinoma cases.
  • CONCLUSIONS: Loss of PTEN expression is relatively common and both cyclin D1 and p27 expressions are not related with PTEN inactivation in clear cell adenocarcinoma of the ovary.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Ovarian Neoplasms / metabolism. PTEN Phosphohydrolase / biosynthesis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16290000.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 136601-57-5 / Cyclin D1; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


15. Kamai T, Tomosugi N, Abe H, Yoshida K: Protein profiling of tumor tissues by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry to discriminate between localized and metastatic renal cell carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e16098

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein profiling of tumor tissues by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry to discriminate between localized and metastatic renal cell carcinoma.
  • : e16098 Background: We previously reported that mRNA of interferon-alpha receptor type 2 (IFNAR2) was upregulated in metastatic and IFN-a resistant renal cell carcinoma (RCC) in comparison to localized RCC or metastatic tumors with good response to IFN-a (BMC Cancer, 2007).
  • Then we selected representative five IFNAR2 upregulated clear cell carcinomas cases with metastatic tumor, five IFNAR2 upregulated metastatic sarcomatoid carcinomas, and five normal expression clear cell carcinomas with localized tumor.
  • Furthermore, the heat map discriminated metastatic sarcomatoid carcinomas from metastatic clear cell carcinomas with a sensitivity of 100% and a specificity of 80%.
  • Our findings may reflect different molecular mechanism between localized and metastatic carcinomas, and the different response to immunotherapy with IFN-α.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963090.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Ravaud A, Oudard S, Gravis-Mescam G, Sevin E, Zanetta S, Théodore C, de Fromont M, Mahier-Aït Oukhatar C, Chêne G, Escudier B: First-line sunitinib in type I and II papillary renal cell carcinoma (PRCC): SUPAP, a phase II study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase trials (GEP). J Clin Oncol; 2009 May 20;27(15_suppl):5146

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First-line sunitinib in type I and II papillary renal cell carcinoma (PRCC): SUPAP, a phase II study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase trials (GEP).
  • : 5146 Background: Sunitinib (Su) has been approved in metastatic clear cell carcinoma due to high objective response rates (ORR) and a prolonged progression-free survival (PFS).
  • Type I and II papillary RCC pts have a poor prognosis, with limited effective agents.
  • SUPAP is exploring type I and II PRCC separately with an identical design.
  • Main eligibility criteria included type I or II PRCC confirmed by central pathological review, PS 0-1, measurable disease, first line of treatment.
  • RESULTS: From 10/07 to 11/08, 5 pts with type I and 23 pts with II PRCC were included.
  • In type II PRCC, 1/23 pts had a partial response (PR), 13/23 pts had a stable disease (SD) with 4 pts with a SD ≥ 12 weeks, 5/23 pts were progressive, 3/23 pts were too early for evaluation and 1/23 was not evaluable.
  • In type I PRCC, none had a partial response (PR), 3/5 pts had stable disease (SD) and 2/5 pts were too early for evaluation.
  • CONCLUSIONS: Although some activity has been observed, response rate was lower than in clear cell tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964444.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Keegan KA, Hellenthal NJ, Chamie K, Koppie TM: Histopathology in surgically treated renal cell carcinoma: Is there a survival difference when stratified by stage? J Clin Oncol; 2009 May 20;27(15_suppl):5089

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathology in surgically treated renal cell carcinoma: Is there a survival difference when stratified by stage?
  • : 5089 Background: The impact of renal cell carcinoma histopathology (RCC) on survival has been conflicting and limited to retrospective institutional studies.
  • Patients were stratified based on histopathologic diagnosis (clear cell, papillary, chromophobe, sarcomatoid, and collecting duct) and pathologic stage.
  • Specifically, patients with papillary and chromophobe variants had lower stage disease at the time of surgery and had improved survival compared to clear cell subtypes, (HR: 0.50; 95% CI, 0.42-0.60 and HR: 0.31; 95% CI, 0.22-0.44, respectively).
  • On the other hand, patients with sarcomatoid disease were more likely to present with high stage disease and invariably had worse survival compared to clear cell carcinoma (HR: 8.74; 95%, CI 7.70-9.91).
  • Patients with sarcomatoid RCC, even those presenting with low-stage disease, have poor survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964288.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Nagao S, Oishi R, Iwasa N, Shimizu M, Hasegawa K, Goto T, Fujiwara K: A feasibility study of intravenous (IV) paclitaxel, intraperitoneal (IP) carboplatin, and IP paclitaxel in patients with epithelial ovarian carcinoma, fallopian tube carcinoma, or peritoneal carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e16549

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A feasibility study of intravenous (IV) paclitaxel, intraperitoneal (IP) carboplatin, and IP paclitaxel in patients with epithelial ovarian carcinoma, fallopian tube carcinoma, or peritoneal carcinoma.
  • : e16549 Background: This is a feasibility study for a future trial to assess the feasibility of intravenous (IV) paclitaxel, intraperitoneal (IP) carboplatin and IP paclitaxel (TCipTip therapy) in patients with epithelial ovarian carcinoma, fallopian tube carcinoma or peritoneal carcinoma.
  • METHODS: The patients eligible for this study had histologically confirmed, stage IC-IV epithelial ovarian carcinoma, fallopian tube carcinoma or peritoneal carcinoma.
  • The patients included 7 epithelial ovarian carcinoma (stage IC, 2; stage IIIC, 5), 2 stage IIIC primary peritoneal carcinoma, and 1 stage IIA fallopian tube carcinoma.
  • There were 7 serous adenocarcinoma, 2 endometrioid adenocarcinoma, 1 clear cell adenocarcinoma.
  • CONCLUSIONS: TCipTip therapy is feasible for patients with epithelial ovarian carcinoma, fallopian tube carcinoma or peritoneal carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960819.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Mendivil A, Vogel TJ, Bae-Jump VL, Gehrig PA: A survival comparison between women with uterine serous and/or clear cell carcinoma with and without a history of breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5580

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A survival comparison between women with uterine serous and/or clear cell carcinoma with and without a history of breast cancer.
  • However, the effect that a prior breast cancer diagnosis may have on women with a new endometrial cancer diagnosis is less well described.
  • The goal of our study was to determine the effect that a prior history of breast cancer would have on the outcome for women with type II uterine cancer.
  • All women treated for uterine carcinoma between 1994 and 2007 were identified and we identified women with either uterine serous (UPSC) or clear cell carcinoma (UCCC) as the study group.
  • The patients were then divided between those with and those without a prior breast cancer diagnosis.
  • Patient demographics, cancer histologies, and stage of disease data were collected.
  • RESULTS: Approximately 1,083 patients were treated for uterine carcinoma during the study period of which 74 had pre-existing breast carcinoma (6.9%).
  • One hundred and fifty women had USC and/or UCCC (13.8%) of whom 23 also had pre-existing breast carcinoma (13.3%).
  • The women with breast cancer where older at the time of their uterine cancer diagnosis (77 y.o.) compared to those without breast cancer (68 y.o.
  • While having two primary malignancies can be devastating, our study indicated that women who developed a type II uterine cancer and also had a history of a prior breast cancer had the same outcomes as those women without a prior cancer diagnosis.
  • This finding may help to allay patients' fears about developing another malignancy and its impact on their prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962613.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Tibau A 1st, Ojeda B 1st, Nadal R 1st, Pérez Altozano J 1st, Boguña I 1st, Artigas V 1st, Gallardo A 1st, Pérez C 1st, Lopez J 1st, Barnadas A 1st: The predictive and prognostic value of serum CA 125 kinetics and CA 125 nadir during paclitaxel/platinum based chemotherapy in patients with advanced ovarian carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e16534

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The predictive and prognostic value of serum CA 125 kinetics and CA 125 nadir during paclitaxel/platinum based chemotherapy in patients with advanced ovarian carcinoma.
  • Tumors were classified: 70 (55%) serous, 24 (19%) poorly differentiated, 14 (11%) endometrioid and 19 (15%) clear cell carcinoma.
  • Residual disease after initial surgery: 52 (41%) optimal <2cm and 39 (31%) suboptimal.
  • Survival analyses for disease-free survival (DFS) and overall survival (OS) used univariate (Kaplan-Meier) and multivariate (Cox) model.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960780.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Kobayashi M, Hattori M, Miyamoto T, Kakinuma H, Watanabe J, Iwabuchi K, Nishimura Y, Jobo T, Kuramoto H: Basement membrane-like substance in cytologic diagnosis in clear cell adenocarcinoma of the minor salivary gland of the palate. A case report. Acta Cytol; 2007 Nov-Dec;51(6):916-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basement membrane-like substance in cytologic diagnosis in clear cell adenocarcinoma of the minor salivary gland of the palate. A case report.
  • BACKGROUND: Clear cell adenocarcinoma (CCA) of the minor salivary gland accounts for < 1% of all tumors of the salivary gland.
  • CASE: A 32-year-old woman with a history of papillary carcinoma of the thyroid 1 year earlier complained of pain on the left side of the neck.
  • Imprint cytology of the tumor revealed cohesive tumor cells of uniform size containing an abundant clear cytoplasm and round nuclei with extra but fine granular chromatin and conspicuous nucleoli.
  • Histopathologic analysis confirmed the trabecular or nest-like arrangement of the cells with the clear cytoplasm and BMS substance surrounded by tumor cells, which were positive for laminin and AE1 immunohistochemically.
  • CONCLUSION: Although CCA of the palate is extremely rare, an accurate cytologic diagnosis can be made if the characteristic findings of CCA, including BMS, are imaged.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Basement Membrane / pathology. Palatal Neoplasms / pathology. Salivary Glands, Minor / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / metabolism. Cytodiagnosis / methods. Disease-Free Survival. Female. Humans. Laminin / metabolism. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18077986.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Laminin
  •  go-up   go-down


22. Sun K, Huan Y, Unger PD: Clear cell adenocarcinoma of urinary bladder and urethra: another urinary tract lesion immunoreactive for P504S. Arch Pathol Lab Med; 2008 Sep;132(9):1417-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell adenocarcinoma of urinary bladder and urethra: another urinary tract lesion immunoreactive for P504S.
  • CONTEXT: Clear cell carcinoma of the urinary bladder/ urethra is a rare tumor histologically resembling the neoplasms in the female genital tract.
  • Adequate characterization of this tumor has been hampered by its rarity. alpha-Methylacyl-CoA racemase (AMACR)/P504S has been reported to be positive in prostatic adenocarcinoma, papillary renal cell carcinoma, and gastrointestinal neoplasmas; however, it has never been studied in clear cell carcinoma of the lower urinary tract.
  • OBJECTIVE: To investigate the immunohistochemical staining profile in 4 primary clear cell carcinomas of the urinary tract, including P504S, which has not been previously evaluated in these tumors.
  • DESIGN: Four cases of clear cell adenocarcinoma were retrieved from our archives: 2 cases from the urinary bladder (one each from a man and a woman) and 2 cases from the urethra (both from women, 1 in a diverticulum).
  • RESULTS: We found that clear cell carcinomas had a distinct immunoreactive profile: strongly positive for P504S, K903, and CK7, and negative for p63.
  • CONCLUSION: The immunohistochemical profile of clear cell carcinomas shares some similarity to conventional urothelial carcinoma; however, it deviates from those tumors in being positive for P504S and negative for p63.
  • This staining profile may suggest a nonurothelial origin for these tumors, may serve as a useful tool in the differential diagnosis of this tumor, and may reflect its etiology.
  • Because similar expression of P504S is also seen in nephrogenic adenomas, this marker should not be used to differentiate nephrogenic adenomas from clear cell adenocarcinomas.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Biomarkers, Tumor / analysis. Racemases and Epimerases / biosynthesis. Urethral Neoplasms / metabolism. Urinary Bladder Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18788852.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / CKAP4 protein, human; 0 / Keratin-20; 0 / Keratin-7; 0 / Membrane Proteins; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


23. Guo YF, Liu AJ, Wang XL, Wu XZ, Song L, Liu HT: [Human papillomavirus detection in clear cell carcinoma of the cervix]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Apr;23(2):82-4
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Human papillomavirus detection in clear cell carcinoma of the cervix].
  • OBJECTIVE: To investigate the infection of the high risk human papillomavirus (HPV) in the specimen of the clear cell carcinoma of the cervix.
  • METHODS: We extracted the nucleic acids in the formalin-fixed and paraffin-embedded specimens from a 37-year-old patient with clear cell carcinoma of the cervix and detected the HPV genotype with the nested PCR.
  • CONCLUSION: The HPV detection with the nested PCR was available for identification of the HPV genotype(s) in the paraffin-embedded specimens of clear cell carcinoma of the cervix (CCCC) with a high accuracy and sensitivity.
  • [MeSH-major] Adenocarcinoma, Clear Cell / virology. Human papillomavirus 18 / isolation & purification. Papillomavirus Infections / virology. Uterine Cervical Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20104741.001).
  • [ISSN] 1003-9279
  • [Journal-full-title] Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology
  • [ISO-abbreviation] Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


24. Kitada M, Ozawa K, Sato K, Hayashi S, Miyokawa N, Sasajima T: Clear cell carcinoma of the lung. Gen Thorac Cardiovasc Surg; 2010 Feb;58(2):87-90
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma of the lung.
  • We present here in the case of a patient who underwent resection of clear cell carcinoma of the lung, a rare histological type.
  • A screening test of the 71-year-old woman revealed a 2.0-cm lesion in S4 of the right lung with a diagnosis of bronchioloalveolar carcinoma before resection.
  • The histopathological examination showed clear, slightly acidophilic tumor cells rich in fine granular components proliferating in an alveolar fashion.
  • Immunostaining was diagnostically useful, distinguishing clear cell carcinoma from lung metastasis of renal clear cell carcinoma or clear cell squamous cell carcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. Aged. Biopsy. Cell Differentiation. Cell Proliferation. Diagnostic Errors. Female. Humans. Immunohistochemistry. Lymph Node Excision. Neoplasm Staging. Predictive Value of Tests. Thoracic Surgery, Video-Assisted. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20155345.001).
  • [ISSN] 1863-6713
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


25. Kanoh A, Seko A, Ideo H, Yoshida M, Nomoto M, Yonezawa S, Sakamoto M, Kannagi R, Yamashita K: Ectopic expression of N-acetylglucosamine 6-O-sulfotransferase 2 in chemotherapy-resistant ovarian adenocarcinomas. Glycoconj J; 2006 Jul;23(5-6):453-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ectopic expression of N-acetylglucosamine 6-O-sulfotransferase 2 in chemotherapy-resistant ovarian adenocarcinomas.
  • Mucinous and clear cell adenocarcinomas are the major histological types of ovarian epithelial cancer and are associated with a poor prognosis due to their resistance to chemotherapy.
  • A novel tumor marker specific for ovarian mucinous and clear cell adenocarcinomas would be helpful for overcoming these serious diseases.
  • We showed previously by enzymological characterization and RT-PCR that colonic mucinous adenocarcinoma tissues ectopically express GlcNAc6ST-2, a member of the carbohydrate 6-O-sulfotransferase family (Seko, A. et al. (2002) Glycobiology 12, 379-388).
  • Here, we prepared a GlcNAc6ST-2-specific polyclonal antibody for immunohistochemical analysis and found that GlcNAc6ST-2 is ectopically expressed by not only colonic mucinous adenocarcinomas but also ovarian mucinous, clear cell and papillary serous adenocarcinomas.
  • In contrast, solid serous adenocarcinomas, endometrioid adenocarcinomas, and mucinous adenomas expressed GlcNAc6ST-2 much less frequently or not at all.
  • RT-PCR analysis confirmed that GlcNAc6ST-2 transcripts are expressed in ovarian mucinous adenocarcinomas but not in mucinous adenomas.
  • In addition, immunohistochemical analysis using sulfated glycan-specific monoclonal antibodies showed that ovarian adenocarcinoma cells express GlcNAc 6-O-sulfated glycans, including an L-selectin ligand and its related glycans.
  • These results indicate that GlcNAc6ST-2 would be a novel tumor antigen that is specifically expressed in ovarian mucinous, clear cell and papillary serous adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / enzymology. Drug Resistance, Neoplasm / physiology. Ovarian Neoplasms / enzymology. Sulfotransferases / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16897186.001).
  • [ISSN] 0282-0080
  • [Journal-full-title] Glycoconjugate journal
  • [ISO-abbreviation] Glycoconj. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; EC 2.8.2.- / Sulfotransferases; EC 2.8.2.- / carbohydrate sulfotransferases
  •  go-up   go-down


26. Shi C, Scudiere JR, Cornish TC, Lam-Himlin D, Park JY, Fox MR, Montgomery EA: Clear cell change in colonic tubular adenoma and corresponding colonic clear cell adenocarcinoma is associated with an altered mucin core protein profile. Am J Surg Pathol; 2010 Sep;34(9):1344-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell change in colonic tubular adenoma and corresponding colonic clear cell adenocarcinoma is associated with an altered mucin core protein profile.
  • Clear cell change is seen in <1% of colonic tubular adenomas (TAs) and remains incompletely characterized.
  • Associated adenocarcinomas can also demonstrate a clear cell phenotype.
  • Eleven TAs with at least focal clear cell change with or without associated invasive adenocarcinoma, from 10 patients were studied.
  • Eight of 11 (77%) TAs with clear cell change had focal to extensive high-grade dysplasia.
  • Two were associated with invasive clear cell adenocarcinoma.
  • The adenomas and adenocarcinomas ranged from 0.5 to 3.5 cm.
  • PAS/PAS-diastase stains showed minimal PAS(+) material in the clear cells.
  • On immunohistochemical studies, the clear cells had decreased MUC2 labeling compared with the surrounding conventional adenoma in 9 of 11 (88%) cases, including the 2 clear cell adenocarcinomas.
  • In 3 of the 11 lesions, the background TA showed at least focal MUC5 immunoreactivity, their associated clear cell area had decreased MUC5 labeling in all 3 cases.
  • No immunoreactivity to MUC6 was observed in the background TAs and clear cells in all cases.
  • Compared with background TA, both increased and decreased expression of CK7, CK20 (in quantity), and CDX2 (in intensity) were observed in the clear cells of TAs and adenocarcinomas.
  • One of the clear cell adenocarcinomas was CK20, CK7, CDX2 and the other was CK20, CK7, CDX2-focal positive.
  • Thus, although the clear cells have different MUC protein profiles than the background adenomatous epithelium, invasive clear cell adenocarcinomas retained the typical CK20(+)/CK7(-) profile of conventional adenocarcinomas.
  • Our results indicate that clear cell adenocarcinomas can be primary to the colorectum with identifiable precursors.
  • Awareness of them and their immunoprofile allows distinction from clear cell lesions from other sites.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Adenoma / pathology. Colonic Neoplasms / pathology. Mucins / metabolism. Rectal Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20697252.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins
  •  go-up   go-down


27. Yabushita H, Kanyama K, Sekiya R, Noguchi M, Wakatsuki A: Clear-cell adenocarcinoma of the uterine cervix in a 17-year-old adolescent. Int J Clin Oncol; 2008 Dec;13(6):552-4
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear-cell adenocarcinoma of the uterine cervix in a 17-year-old adolescent.
  • This report describes the case of the youngest Japanese person to be diagnosed with endocervical clearcell adenocarcinoma.
  • The cytological finding of the uterine cervix was positive for malignancy, and the histological diagnosis by punch biopsy was clear-cell adenocarcinoma of the uterine cervix.
  • The pathological diagnosis was clear-cell adenocarcinoma of the cervix (PT1b1NR0M0).
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19093185.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


28. Vrdoljak-Mozetic D, Stanković T, Krasević M, Versa-Ostojić D, Stemberger-Papić S, Rupcić S: Intraoperative cytology of clear cell carcinoma of the ovary. Cytopathology; 2006 Dec;17(6):390-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative cytology of clear cell carcinoma of the ovary.
  • OBJECTIVE: To describe the cytomorphology of clear cell carcinoma (CCC) of the ovary in intraoperative samples of peritoneal fluid, imprint and scraping samples of the tumour tissue.
  • RESULTS: In 33.3% of peritoneal fluid samples and 92.9% of imprint and scraping cytological samples, besides variable clear cell cellular morphology, one or both distinct cytological characteristics were observed: eosinophilic, hyaline, extracellular, globular substance with or without formation of a 'raspberry' body and an eosinophilic, intracytoplasmic inclusions.
  • CONCLUSION: Using cytological analysis of imprint and scraping samples of ovarian tumours it is possible to make a precise intraoperative cytological diagnosis in most cases of CCC of the ovary.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17168923.001).
  • [ISSN] 0956-5507
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


29. Markopoulos C, Mantas D, Philipidis T, Kouskos E, Antonopoulou Z, Hatzinikolaou M, Gogas H: Glycogen-rich clear cell carcinoma of the breast. World J Surg Oncol; 2008;6:44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glycogen-rich clear cell carcinoma of the breast.
  • BACKGROUND: Glycogen-rich carcinoma of the breast is a rare histological subtype of breast cancer, usually reported to have poor prognosis.
  • CASE PRESENTATION: We present the case of a 59-year-old woman who underwent a mastectomy for a 3.5 cm clinically palpable left breast carcinoma, originally diagnosed as fibroadenoma on a screening mammogram four years before presentation.
  • Diagnosis of clear cell carcinoma was based on certain histological characteristics of the tumour and immunohistochemical analysis (PAS staining, keratins AE1/AE3, EMA, cytokeratin 7, cytokeratin 20, melanosomes, vimentin, Chromogranin, Synaptophysin, S-100, SMA).
  • No lymph node metastasis was found and as the tumour was ER positive and PgR negative, patient was treated only with an aromatase inhibitor upfront and remains free of disease 48 months now since operation.
  • CONCLUSION: Glycogen-rich clear cell carcinoma of the breast is a rare tumor, its clinical behavior reported to be rather aggressive so far, might varies depending on special characteristics such as low grade and strongly positive ER expression.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Breast Neoplasms / pathology. Glycogen / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1973 Apr;31(4):793-800 [4350331.001]
  • [Cites] Yale J Biol Med. 1971 Feb-Apr;43(4-5):213-22 [5578741.001]
  • [Cites] Hum Pathol. 1975 May;6(3):384-90 [1132876.001]
  • [Cites] J Pathol Bacteriol. 1964 Jan;87:25-7 [14106350.001]
  • [Cites] Am J Surg Pathol. 1995 Aug;19(8):904-11 [7611537.001]
  • [Cites] Hum Pathol. 1991 Jan;22(1):81-3 [1985082.001]
  • [Cites] Cancer. 1981 Nov 1;48(9):2003-9 [6271388.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1980 Mar-Apr;89(2 Pt 1):168-72 [7189393.001]
  • [Cites] Cancer. 1976 May;37(5):2355-8 [1260721.001]
  • [Cites] Arch Pathol Lab Med. 1977 Mar;101(3):140-4 [576578.001]
  • [Cites] Pathology. 1977 Oct;9(4):341-6 [593733.001]
  • [Cites] Am J Clin Pathol. 1980 Jan;73(1):31-5 [6243441.001]
  • (PMID = 18442419.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 9005-79-2 / Glycogen
  • [Other-IDs] NLM/ PMC2386120
  •  go-up   go-down


30. Lee JY, Im ES, Kim SW, Kim H, Kim YB, Jeon YT: A case of clear cell carcinoma arising from the endometriosis of the paraovarian cyst. J Gynecol Oncol; 2009 Mar;20(1):60-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of clear cell carcinoma arising from the endometriosis of the paraovarian cyst.
  • Malignant transformation of endometriosis is an infrequent complication.
  • Clear cell carcinoma from endometriosis is very rare in the paraovarian cyst.
  • We report a case of clear cell carcinoma arising from endometriosis of the paraovarian cyst with a brief review of literature.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1998 Nov;71(2):313-6 [9826478.001]
  • [Cites] Obstet Gynecol. 1990 Jun;75(6):1023-8 [2188180.001]
  • [Cites] Obstet Gynecol. 1984 Sep;64(3 Suppl):60S-63S [6472751.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1980 Dec;11(3):195-200 [7194811.001]
  • [Cites] Acta Obstet Gynecol Scand. 1974;53(2):185-9 [4822349.001]
  • [Cites] Am J Obstet Gynecol. 1979 Mar 1;133(5):585-6 [443297.001]
  • [Cites] Acta Pathol Microbiol Scand Suppl. 1972;233:98-102 [4342325.001]
  • [Cites] Acta Obstet Gynecol Scand. 1971;50(1):63-7 [4326871.001]
  • [Cites] Hum Pathol. 1981 Sep;12(9):845-8 [7309034.001]
  • (PMID = 19471669.001).
  • [ISSN] 2005-0380
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2676499
  • [Keywords] NOTNLM ; Clear cell carcinoma / Endometriosis / Paraovarian cyst
  •  go-up   go-down


31. Martínez-Rodríguez R, Rodríguez-Escovar F, Bujons Tur A, Maroto P, Palou J, Villavicencio H: [Skin metastasis during follow-up of a clear cell renal carcinoma]. Arch Esp Urol; 2008 Jan-Feb;61(1):80-2
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Skin metastasis during follow-up of a clear cell renal carcinoma].
  • [Transliterated title] Metástasis cutánea durante el seguimiento de carcinoma renal de celulas claras.
  • OBJECTIVE: To report a new case of metastatic renal carcinoma with atypical localization.
  • It is usually associated with internal organ involvement, so that this finding makes prognosis poor.
  • METHODS: We present the case of a 60-year-old male patient with the diagnosis of inferior maxillary skin metastasis 18 months after radical nephrectomy for clear cell adenocarcinoma.
  • Two years after diagnosis the patient is alive and a disease-free.
  • CONCLUSIONS: The wide variability of localizations and forms of presentation of metastatic renal carcinoma obliges to be alert during followup.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology. Skin Neoplasms / secondary


32. Chaudhry IH, Zembowicz A: Adnexal clear cell carcinoma with comedonecrosis: clinicopathologic analysis of 12 cases. Arch Pathol Lab Med; 2007 Nov;131(11):1655-64
MedlinePlus Health Information. consumer health - Acne.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adnexal clear cell carcinoma with comedonecrosis: clinicopathologic analysis of 12 cases.
  • CONTEXT: Cutaneous clear cell tumors can pose a diagnostic challenge even to the experienced dermatopathologist; this is partly because of limitations of existing diagnostic categories.
  • OBJECTIVE: To describe a previously unrecognized, distinctive cutaneous adnexal carcinoma capable of an aggressive clinical course.
  • Histologically, adnexal clear cell carcinoma with comedonecrosis was characterized by dermal proliferation of nests of epithelial cells showing distinctive zonal arrangement.
  • The periphery of the tumor nests was formed by squamoid cells merging with centrally located clear cell areas containing foci of comedonecrosis.
  • All cases showed expression of epithelial membrane antigen and cytokeratin 17 in clear cells, with focal carcinoembryonic antigen expression in some cases.
  • CONCLUSIONS: Adnexal clear cell carcinoma with comedonecrosis appears to be a distinctive adnexal neoplasm that has to be distinguished from more indolent squamous cell and tricholemmal carcinomas.
  • [MeSH-major] Acne Vulgaris / pathology. Carcinoma, Squamous Cell / pathology. Neoplasms, Adnexal and Skin Appendage / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoembryonic Antigen / metabolism. Cell Proliferation. Diagnosis, Differential. Epithelial Cells / metabolism. Epithelial Cells / pathology. Female. Humans. Keratin-17 / metabolism. Male. Middle Aged. Mucin-1 / metabolism. Necrosis / metabolism. Necrosis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Pathol Lab Med. 2011 May;135(5):532; author reply 533 [21526948.001]
  • (PMID = 17979483.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Mucin-1
  •  go-up   go-down


33. Crotzer DR, Sun CC, Coleman RL, Wolf JK, Levenback CF, Gershenson DM: Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol; 2007 May;105(2):404-8
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary.
  • OBJECTIVE: Clear cell carcinoma of the ovary is an aggressive tumor characterized by relative chemoresistance and a poor prognosis.
  • The purpose of this study was to review our experience with recurrent clear cell carcinoma of the ovary to evaluate its responsiveness to systemic cytotoxic and hormonal agents.
  • METHODS: All patients diagnosed with clear cell carcinoma of the ovary seen at our institution between 1990 and 2002 were identified and their medical records reviewed.
  • 1) primary diagnosis of clear cell carcinoma of the ovary, 2) measurable recurrent disease, 3) treatment of recurrent disease with 1 or more systemic regimens, and 4) adequate clinical information.
  • RESULTS: Fifty-one patients treated for recurrent clear cell carcinoma were identified.
  • Among patients with platinum-sensitive disease (n=22 regimens), 2 patients (9%) had partial responses to retreatment with carboplatin plus paclitaxel, and 4 (18%) had stable disease.
  • Among patients with platinum-resistant disease (n=83 regimens), only 1 patient (1%) had a partial response - to gemcitabine - and 1 patient had stable disease in response to 2 different regimens-paclitaxel and gemcitabine.
  • CONCLUSION: Our findings suggest that recurrent clear cell carcinoma of the ovary is particularly chemoresistant.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17292461.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; Q41OR9510P / Melphalan
  •  go-up   go-down


34. Choi HJ, Lee JH, Seok Lee J, Choi JI, Kang S, Lee S, Seo SS, Park SY: CT findings of clear cell carcinoma of the ovary. J Comput Assist Tomogr; 2006 Nov-Dec;30(6):875-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CT findings of clear cell carcinoma of the ovary.
  • PURPOSE: The purpose of this article was to retrospectively evaluate computed tomographic (CT) findings in patients with pathologically proved clear cell carcinoma of the ovary.
  • METHODS: CT scans of seven patients (age range, 28-79 years; mean age, 46 years) with nine lesions of histologically proved primary ovarian clear cell carcinoma of the ovary were retrospectively evaluated by two radiologists in consensus.
  • CONCLUSION: On CT scans, primary ovarian clear cell carcinomas appeared as large unilocular, mainly cystic, smooth marginated mass with lumen protruding solid portion and high-attenuated cystic portion.
  • [MeSH-major] Carcinoma, Renal Cell / radiography. Ovarian Neoplasms / radiography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17082688.001).
  • [ISSN] 0363-8715
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Kato N, Takeda J, Fukase M, Motoyama T: Alternate mucoid and hyalinized stroma in clear cell carcinoma of the ovary: manifestation of serial stromal remodeling. Mod Pathol; 2010 Jun;23(6):881-8
Hazardous Substances Data Bank. HYALURONIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alternate mucoid and hyalinized stroma in clear cell carcinoma of the ovary: manifestation of serial stromal remodeling.
  • The stroma in ovarian clear cell carcinoma often shows alternate mucoid and hyalinized change.
  • We examined 60 ovarian clear cell carcinomas for the distribution and nature of the mucoid stroma.
  • Twenty-nine of 60 (48%) clear cell carcinomas showed a mucoid stroma, either focally (21 cases) or diffusely (8 cases).
  • The mucoid stroma in clear cell carcinomas was distinct from that in other surface epithelial tumors as follows: it showed a compact spherule-like appearance, commonly occupying the cores of small papillae.
  • It also exhibited a cribriform pattern, resembling that of adenoid cystic carcinoma.
  • Among 40 clear cell carcinomas that had at least one type of stroma, 26 (65%) had both, either concomitantly or separately.
  • In vitro, a clear cell carcinoma cell line, HAC-2, formed a spherule-like structure containing hyaluronan in the center, and a significant amount of hyaluronan was detected by latex agglutination immunoturbidimetry, indicating that HAC-2 itself has the potential to produce hyaluronan.
  • All of these facts indicate that the spherule-like mucoid stroma and hyalinized stroma represent different phases of the stromal remodeling process, which is promoted by the deposition of different extracellular matrices produced by clear cell carcinoma cells.
  • The spherule-like mucoid stroma and hyalinized stroma are considered complementary diagnostic signatures of ovarian clear cell carcinoma.
  • [MeSH-major] Carcinoma / metabolism. Extracellular Matrix / metabolism. Hyaluronic Acid / metabolism. Mucins / metabolism. Ovarian Neoplasms / metabolism. Stromal Cells / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Animals. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Cell Line, Tumor. Female. Humans. Immunohistochemistry. Mice. Mice, Inbred BALB C. Mice, Nude. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20305617.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucins; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


36. Orezzoli JP, Russell AH, Oliva E, Del Carmen MG, Eichhorn J, Fuller AF: Prognostic implication of endometriosis in clear cell carcinoma of the ovary. Gynecol Oncol; 2008 Sep;110(3):336-44
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic implication of endometriosis in clear cell carcinoma of the ovary.
  • OBJECTIVE: The aim of this study is to investigate whether the presence of endometriosis is a prognostic factor in patients diagnosed with clear cell carcinoma (CCC) of the ovary.
  • Advanced tumor stage at diagnosis (HR 13, 95% C.I.
  • Disease recurrence or death among optimally and completely cytoreduced patients was 31% and 59% for those with and without endometriosis respectively (P>0.05).
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Endometriosis / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18639330.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds
  •  go-up   go-down


37. Fennessy BG, Sheahan P, Toner M, Timon C: A subcutaneous mandibulotomy approach for a salivary clear cell carcinoma of the retromolar trigone. Ir J Med Sci; 2010 Mar;179(1):147-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A subcutaneous mandibulotomy approach for a salivary clear cell carcinoma of the retromolar trigone.
  • OBJECTIVE: We report a novel subcutaneous mandibulotomy approach for the excision of a rare clear cell carcinoma, not otherwise specified (NOS) of the retromolar trigone.
  • METHOD: Case reports and a review of the medical literature concerning clear cell carcinoma and subcutaneous mandibulotomy are discussed.
  • Clear cell carcinoma, NOS is a rare condition, with few reports in the literature.
  • CONCLUSION: This is the first occasion a subcutaneous mandibulotomy approach for an oral tumour has been described in Great Britain and Ireland, the second reported case of clear cell carcinoma originating in the retromolar trigone region and only the fourth case of associated lymph nodal metastases.
  • [MeSH-major] Adenocarcinoma, Clear Cell / surgery. Mandible / surgery. Mandibular Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18696176.001).
  • [ISSN] 1863-4362
  • [Journal-full-title] Irish journal of medical science
  • [ISO-abbreviation] Ir J Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 8
  •  go-up   go-down


38. Gadducci A, Cosio S, Spirito N, Cionini L: Clear cell carcinoma of the endometrium: a biological and clinical enigma. Anticancer Res; 2010 Apr;30(4):1327-34
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma of the endometrium: a biological and clinical enigma.
  • Clear cell carcinoma accounts for only 1 to 5.5% of all endometrial carcinomas, and it is often associated with an aggressive clinical behavior and a poor outcome.
  • According to the FIGO Annual Report 2006, 5-year overall survival was 62.5% for patients with this histological type compared with 83.2% for those with endometrioid carcinoma of the endometrium.
  • In contrast to endometrioid carcinoma and uterine papillary serous carcinoma (UPSC), the molecular pathways involved in the development of clear cell carcinoma are still unclear.
  • Literature data on the pattern of failures and the optimal treatment modalities of the clear cell carcinoma are not well defined, largely because most papers have assessed clear cell carcinoma and UPSC together because of their rarity.
  • Patients with clear cell carcinoma often experience relapse in the pelvis, in para-aortic nodes and at distant sites, whereas they do not seem to have a high propensity to fail in the abdomen.
  • Total abdominal hysterectomy and bilateral salpingo-oophorectomy with comprehensive surgical staging is the standard surgical treatment of patients with clear cell carcinoma of the endometrium, whereas pelvic irradiation, with or without brachytherapy and/or para-aortic irradiation, whole-abdomen irradiation, and chemotherapy have been widely employed as postoperative therapy.
  • An adequate molecular characterization of clear cell carcinoma of the endometrium is strongly warranted in order to identify new biological prognostic variables of the disease and to develop novel molecular targeted therapies.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / therapy. Endometrial Neoplasms / pathology. Endometrial Neoplasms / therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20530448.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Number-of-references] 73
  •  go-up   go-down


39. Tan YT, Zhang X, Lin ZQ, Chen Q, Wang LJ, Zhang BZ: [Primary clear cell carcinoma of the cervix: report of five cases and review of the literature]. Zhonghua Fu Chan Ke Za Zhi; 2008 Feb;43(2):120-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary clear cell carcinoma of the cervix: report of five cases and review of the literature].
  • OBJECTIVE: To explore the clinical diagnostic and therapeutic characteristics, prognostic factors of patients with primary clear cell carcinoma of the cervix.
  • METHODS: The clinical, pathologic and follow-up data of patients with primary clear cell carcinoma of the cervix treated in our hospital from Jan 2003 to Dec 2006 were collected and analyzed retrospectively.
  • RESULTS: Five patients with primary clear cell carcinoma of the cervix were treated (1 case stage I b1, 2 of stage I b2, 1 of stage IIa, 1 of stage IVa).
  • The primary symptom was mostly irregularly vaginal bleeding (3/5) and clinical type was predominantly (4/5) endophytic growth.
  • CONCLUSIONS: Primary clear cell carcinoma of the cervix may be unrelated to HPV infection.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. CA-125 Antigen / blood. Uterine Cervical Neoplasms / pathology


40. Hentati D, Belghith B, Kochbati L, Driss M, Maalej M: Clear cell carcinoma of the uterus. Tunis Med; 2010 Apr;88(4):230-3
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma of the uterus.
  • AIM: The aim of this study was to determine the characteristics and outcome of patients presenting with clear cell carcinoma (CCC) of the endometrium treated in a single institution.
  • Pathological features were studied in order to determine predictif factors of extrauterine disease extention and failure patterns.
  • The mean age at diagnosis was 64 years (50 to 84 yers).
  • CONCLUSION: Extrauterine extension is frequent at diagnosis and not correlated to classical risk factors observed in endometrioid carcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Uterine Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20446254.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


41. Goodheart MJ, Rose SL, Hattermann-Zogg M, Smith BJ, De Young BR, Buller RE: BRCA2 alteration is important in clear cell carcinoma of the ovary. Clin Genet; 2009 Aug;76(2):161-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BRCA2 alteration is important in clear cell carcinoma of the ovary.
  • BRCA2 has been shown to play a significant role in hereditary ovarian carcinoma.
  • Several cases of clear cell carcinoma (CCC) of the ovary containing BRCA2 mutations have been identified.
  • The 5-year disease-specific survival probability for patients with a BRCA2 alteration is 87.5%, compared to only 40% for those patients without a BRCA2 alteration (p = 0.39).
  • [MeSH-major] Adenocarcinoma, Clear Cell / genetics. BRCA2 Protein / genetics. Mutation / genetics. Ovarian Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19656163.001).
  • [ISSN] 1399-0004
  • [Journal-full-title] Clinical genetics
  • [ISO-abbreviation] Clin. Genet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / BRCA2 Protein
  •  go-up   go-down


42. Pujary K, Rangarajan S, Nayak DR, Balakrishnan R, Ramakrishnan V: Hyalinizing clear cell carcinoma of the base of tongue. Int J Oral Maxillofac Surg; 2008 Jan;37(1):93-6
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyalinizing clear cell carcinoma of the base of tongue.
  • Hyalinizing clear cell carcinoma is a rare, low-grade neoplasm of the minor salivary glands.
  • It is composed exclusively of epithelial cells with optically clear cytoplasm.
  • Once confirmed by biopsy, the hyalinizing clear cell carcinoma was resected via a transcervical approach.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Salivary Gland Neoplasms / pathology. Tongue Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17822882.001).
  • [ISSN] 0901-5027
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


43. Kawagishi N, Shirahata Y, Ishida K, Satoh K, Enomoto Y, Akamatsu Y, Sekiguchi S, Fukumori T, Fujimori K, Satoh A, Moriya T, Satomi S: Hepatic resection of giant metastatic tumor from clear cell carcinoma of the ovary. J Hepatobiliary Pancreat Surg; 2005;12(2):155-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic resection of giant metastatic tumor from clear cell carcinoma of the ovary.
  • All cancer patients, particularly those treated for colorectal cancer, should be monitored for the presence of liver metastases, but liver metastases from ovarian clear cell carcinoma are quite rare.
  • We report a patient subjected to extended left hepatectomy due to a giant metastasis 5 years after surgical treatment for an ovarian neoplasm that was histopathologically diagnosed as clear cell carcinoma.
  • The tumor compressed the inferior vena cava (IVC), but it was not clear whether it invaded the vessel.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / secondary. Hepatectomy. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868082.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


44. Bukowski RM: Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab. Cancer Manag Res; 2010 Mar 26;2:83-96

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab.
  • The biology and pathogenesis of clear cell carcinoma of the kidney has been extensively investgated, and the role of von Hipple-Landau gene inactivation and tumor associated angiogenesis is now recognized.
  • Development of vascular endothelial growth factor inhibitors and phase 3 clinical trials utilizing this class of agents has produced a new treatment paradigm for patients with metastatic renal cell carcinoma (RCC).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21188099.001).
  • [ISSN] 1179-1322
  • [Journal-full-title] Cancer management and research
  • [ISO-abbreviation] Cancer Manag Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3004565
  • [Keywords] NOTNLM ; bevacizumab / interferon-α / metastatic renal cell carcinoma
  •  go-up   go-down


45. Miao Y, Cai B, Liu L, Yang Y, Wan X: Annexin IV is differentially expressed in clear cell carcinoma of the ovary. Int J Gynecol Cancer; 2009 Dec;19(9):1545-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Annexin IV is differentially expressed in clear cell carcinoma of the ovary.
  • OBJECTIVE: To investigate the genes that were differentially expressed between clear cell carcinoma (CCC) and serous carcinoma (SAC) of the ovary with complementary DNA microarray.
  • The verification of Annexin IV in the cell line and tissues was in accordance with the result of the microarray.
  • CONCLUSIONS: The complementary DNA microarray technique is a feasible way to explore the difference of the gene expression profiling between the 2 types of ovarian carcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / genetics. Annexin A4 / genetics. Ovarian Neoplasms / genetics
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Cell Line, Tumor. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Female. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Oligonucleotide Array Sequence Analysis. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19955935.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Annexin A4; 0 / Biomarkers, Tumor
  •  go-up   go-down


46. Uzochukwu NO, Shrier DA, Lapoint RJ: Clear cell carcinoma of the base of the tongue: MR imaging findings. AJNR Am J Neuroradiol; 2007 Jan;28(1):127-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma of the base of the tongue: MR imaging findings.
  • Clear cell carcinoma of the base of the tongue is a rare minor salivary gland neoplasm, and to our knowledge, the MR imaging appearance of this entity has not been described.
  • We present the MR imaging findings in such a case and review the differential diagnosis for tongue base masses in an adult.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Magnetic Resonance Imaging. Salivary Gland Neoplasms / diagnosis. Salivary Glands, Minor. Tongue Neoplasms / diagnosis
  • [MeSH-minor] Biopsy. Deglutition Disorders / etiology. Diagnosis, Differential. Female. Humans. Laryngoscopy. Middle Aged. Tongue / pathology. Tongue / surgery

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17213438.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Takami M, Kita E, Kuwana Y, Ohta Y, Nakayama Y, Fukai H, Matsumoto H, Takimoto T, Ichikawa G, Yamamoto T: [A case of brain metastasis from advanced ovarian clear-cell carcinoma during maintenance chemotherapy with irinotecan+cisplatin]. Gan To Kagaku Ryoho; 2008 Jul;35(7):1243-5
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of brain metastasis from advanced ovarian clear-cell carcinoma during maintenance chemotherapy with irinotecan+cisplatin].
  • Clear-cell carcinoma of the ovary is a highly malignant neoplasm.
  • Survival of patients in the advanced stage is poor, and the best treatment is not clear.
  • We report here a case of a 57-year-old woman who had Stage IIIb advanced clearcell carcinoma of the ovary.
  • Considering the poor prognosis of clear-cell carcinoma, this regimen is thought to be effective for advanced clear-cell carcinoma of the ovary.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / pathology. Brain Neoplasms / drug therapy. Camptothecin / analogs & derivatives. Cisplatin / therapeutic use. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633273.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


48. Oishi T, Itamochi H, Kigawa J, Kanamori Y, Shimada M, Takahashi M, Shimogai R, Kawaguchi W, Sato S, Terakawa N: Galectin-3 may contribute to Cisplatin resistance in clear cell carcinoma of the ovary. Int J Gynecol Cancer; 2007 Sep-Oct;17(5):1040-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Galectin-3 may contribute to Cisplatin resistance in clear cell carcinoma of the ovary.
  • Our previous findings suggested that lower cell proliferation of clear cell carcinoma (CCC) of the ovary may contribute to its resistance to chemotherapy.
  • We conducted the present study to find the gene that regulates cell proliferation of CCC and to elucidate whether it contributes to cisplatin (CDDP) resistance.
  • Complementary DNA microarray analysis revealed that the gene expression level of galectin-3 of CCC cell lines (KK, RMG-I, HAC-2) was over threefold higher than that of ovarian serous adenocarcinoma (SAC) cell lines (HRA, KF).
  • The present study showed that the expression of galectin-3 in CCC might contribute to its lower cell proliferation and lead to CDDP resistance.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Drug Resistance, Neoplasm / genetics. Galectin 3 / physiology. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Apoptosis. Cell Line, Tumor. Cisplatin / therapeutic use. Cyclin-Dependent Kinase Inhibitor p27 / genetics. Cyclin-Dependent Kinase Inhibitor p27 / metabolism. Female. Humans. Immunohistochemistry. RNA, Small Interfering / pharmacology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17433067.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Galectin 3; 0 / RNA, Small Interfering; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


49. Yamashita R, Yamaguchi R, Yuen K, Niwakawa M, Tobisu K: [Primary clear cell carcinoma of the ureter: a case report]. Nihon Hinyokika Gakkai Zasshi; 2006 Mar;97(3):607-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary clear cell carcinoma of the ureter: a case report].
  • The pathological diagnosis was clear cell carcinoma with small foci of conventional urothelial carcinoma of the left ureter (pT3pN0, G3 > G2, INFgamma).
  • This is the first case report of clear cell carcinoma of the ureter in Japan.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Clear Cell / surgery. Ureteral Neoplasms / diagnosis. Ureteral Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613164.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


50. Maestre-Rodríguez O, González-García R, Mateo-Arias J, Moreno-García C, Serrano-Gil H, Villanueva-Alcojol L, Campos-de-Orellana AM, Monje-Gil F: Metastasis of renal clear-cell carcinoma to the oral mucosa, an atypical location. Med Oral Patol Oral Cir Bucal; 2009 Nov;14(11):e601-4
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of renal clear-cell carcinoma to the oral mucosa, an atypical location.
  • The most common primary tumors metastasizing to the mouth are lung carcinoma in men and breast carcinoma in women.
  • An oral metastasis implies a serious prognosis, as in the majority of patients there is multiple organ involvement at the time of diagnosis.
  • With the provisional clinical diagnosis of a pyogenic granuloma,the tumor was excised.
  • Subsequent anatomopathological analysis revealed a tumor metastasis compatible with clear-cell carcinoma, and its renal origin was confirmed by means of immunohistochemical techniques.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology. Mouth Mucosa. Mouth Neoplasms / secondary


51. Ray B, New NE, Wedgwood KR: Clear cell carcinoma of exocrine pancreas: a rare tumor with an unusual presentation. Pancreas; 2005 Mar;30(2):184-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma of exocrine pancreas: a rare tumor with an unusual presentation.
  • Metastatic clear cell carcinomas are relatively common from primary tumors arising in the kidney, female genital tract, adrenal cortex, and lung, but they rarely occur from primary tumors of the pancreas.
  • We report a case of metastatic pancreatic tumor with marked clear cell changes in a 46-year-old white man presenting with a pseudocyst of the pancreas.
  • The histologic and immunohistochemical test of the excised omental nodule exhibited features consistent with clear cell carcinoma from pancreatic primary.
  • To our knowledge, this is the first report of a metastatic clear cell pancreatic tumor with such an unusual presentation.
  • [MeSH-major] Adenocarcinoma, Clear Cell / secondary. Omentum / pathology. Pancreas, Exocrine / pathology. Pancreatic Neoplasms / pathology. Pancreatic Pseudocyst / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15714142.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Liu Z, Ma W, Li H, Li Q: Clinicopathological and prognostic features of primary clear cell carcinoma of the liver. Hepatol Res; 2008 Mar;38(3):291-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological and prognostic features of primary clear cell carcinoma of the liver.
  • AIM: Primary clear cell carcinoma of the liver (PCCCL) is a subgroup of primary hepatocellular carcinoma (HCC), pathologically characterized by diffuse clear cells of the tumor, showing a clear cytoplasm that does not stain with hematoxylin-eosin.
  • RESULTS: The chi(2)-test showed a positive rate of hepatitis C virus (HCV) infection and capsule formation in the PCCCL group, which was markedly higher than in the common type HCC (CHCC) group (P = 0.000 and P = 0.005).
  • The prognosis of patients in the PCCCL group was related to capsule formation, vascular invasion, liver cirrhosis, and clear cell ratio.
  • The 1-, 3-, and 5-year survival rates were markedly higher in the group with a higher clear cell ratio than in the group with a lower clear cell ratio (P = 0.011).
  • The prognosis was better than that of the patients in the CHCC group and related to the ratio of clear cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17877725.001).
  • [ISSN] 1386-6346
  • [Journal-full-title] Hepatology research : the official journal of the Japan Society of Hepatology
  • [ISO-abbreviation] Hepatol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


53. Tong GX, Weeden EM, Hamele-Bena D, Huan Y, Unger P, Memeo L, O'Toole K: Expression of PAX8 in nephrogenic adenoma and clear cell adenocarcinoma of the lower urinary tract: evidence of related histogenesis? Am J Surg Pathol; 2008 Sep;32(9):1380-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of PAX8 in nephrogenic adenoma and clear cell adenocarcinoma of the lower urinary tract: evidence of related histogenesis?
  • Both are cell lineage restricted transcription factors expressed in normal and neoplastic tissues of related origin, including renal tubular cells in both fetal and adult kidneys.
  • We report here that PAX8 was detected in all nephrogenic adenomas (N=35) and clear cell adenocarcinoma of the lower urinary tract (N=7), but not in prostate adenocarcinoma (N=100), adenocarcinoma (N=9), squamous cell carcinoma (N=5), or urothelial carcinoma (N=48) of the urinary bladder and its variants.
  • PAX2 was also detected in 2 of the 7 clear cell adenocarcinomas of the lower urinary tract.
  • Expression of PAX8 or PAX2 in both nephrogenic adenoma and clear cell adenocarcinoma of the lower urinary tract may indicate a possible related tissue origin for these 2 lesions; both may be derived from proliferating renal tubular cells in the urinary tract.
  • In addition, detection of PAX8 or PAX2 in clear cell adenocarcinoma of the lower urinary tract is helpful in differentiating it from urothelial carcinoma and its variants and adenocarcinomas of the urinary bladder or of the prostate.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Adenoma / metabolism. Biomarkers, Tumor / analysis. Paired Box Transcription Factors / biosynthesis. Urologic Neoplasms / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670350.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PAX2 Transcription Factor; 0 / PAX2 protein, human; 0 / PAX8 protein, human; 0 / Paired Box Transcription Factors
  •  go-up   go-down


54. Ye XP, Li LQ, Peng T, Xiao KY, Su ZX, Shang LM, Su M, Xu BH: [Diagnosis and treatment of primary clear cell carcinoma of the liver]. Zhonghua Zhong Liu Za Zhi; 2010 Jan;32(1):64-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of primary clear cell carcinoma of the liver].
  • OBJECTIVE: To investigate the clinicopathological features, diagnosis, treatment and prognosis of primary clear cell carcinoma of the liver (PCCCL).
  • CONCLUSION: The clinical characteristics of primary clear cell carcinoma of the liver are similar to that of common hepatocellular carcinoma.
  • It is difficult to be diagnosed preoperatively and final diagnosis depends on pathological examination.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Hepatectomy. Liver Neoplasms / pathology. Liver Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20211073.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


55. Bats AS, Zafrani Y, Pautier P, Duvillard P, Morice P: Malignant transformation of abdominal wall endometriosis to clear cell carcinoma: case report and review of the literature. Fertil Steril; 2008 Oct;90(4):1197.e13-6
MedlinePlus Health Information. consumer health - Endometriosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of abdominal wall endometriosis to clear cell carcinoma: case report and review of the literature.
  • OBJECTIVE: To report a case of clear cell carcinoma in abdominal wall endometriosis after cesarean section.
  • RESULT(S): The diagnosis of clear cell carcinoma in abdominal wall endometriosis was confirmed, and wide surgical excision with abdominal wall reconstruction was performed after three courses of chemotherapy.
  • CONCLUSION(S): The malignant transformation of abdominal wall endometrioma has not been clearly elucidated, owing to its rarity.
  • [MeSH-major] Abdominal Neoplasms / pathology. Abdominal Neoplasms / surgery. Abdominal Wall / pathology. Abdominal Wall / surgery. Endometriosis / pathology. Endometriosis / surgery. Sarcoma, Clear Cell / pathology. Sarcoma, Clear Cell / surgery
  • [MeSH-minor] Adult. Cell Transformation, Neoplastic. Female. Humans

  • Genetic Alliance. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18082734.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 13
  •  go-up   go-down


56. Lester FC, Farmer DL, Rabban JT, Chen LM: Radical trachelectomy for clear cell carcinoma of the cervix in a 6-year old: a case report, review, and description of the surgical technique. J Pediatr Surg; 2010 Aug;45(8):E1-5
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical trachelectomy for clear cell carcinoma of the cervix in a 6-year old: a case report, review, and description of the surgical technique.
  • Clear cell carcinoma is a rare pediatric cervical cancer, seen primarily in the setting of in utero diethylstilbesterol exposure.
  • Historically, this type of cancer has been treated with radical hysterectomy and lymph-node dissection, rendering patients incapable of carrying a pregnancy in the future.
  • We describe a young patient with clear cell carcinoma of the cervix who, through a multidisciplinary collaboration, was managed by a fertility-sparing alternative surgical approach--a radical trachelectomy.
  • [MeSH-major] Adenocarcinoma, Clear Cell / surgery. Fertility / physiology. Gynecologic Surgical Procedures / methods. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20713196.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


57. Liu L, Qian J, Singh H, Meiers I, Zhou X, Bostwick DG: Immunohistochemical analysis of chromophobe renal cell carcinoma, renal oncocytoma, and clear cell carcinoma: an optimal and practical panel for differential diagnosis. Arch Pathol Lab Med; 2007 Aug;131(8):1290-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical analysis of chromophobe renal cell carcinoma, renal oncocytoma, and clear cell carcinoma: an optimal and practical panel for differential diagnosis.
  • CONTEXT: The separation of chromophobe renal cell carcinoma, oncocytoma, and clear cell renal cell carcinoma using light microscopy remains problematic in some cases.
  • OBJECTIVE: To determine a practical immunohistochemical panel for the differential diagnosis of chromophobe carcinoma.
  • DESIGN: Vimentin, glutathione S-transferase alpha (GST-alpha), CD10, CD117, cytokeratin (CK) 7, and epithelial cell adhesion molecule (EpCAM) were investigated in 22 cases of chromophobe carcinoma, 17 cases of oncocytoma, and 45 cases of clear cell carcinoma.
  • RESULTS: Vimentin and GST-alpha expression were exclusively observed in clear cell carcinoma.
  • CD10 staining was more frequently detected in clear cell carcinoma (91%) than in chromophobe carcinoma (45%) and oncocytoma (29%).
  • CD117 was strongly expressed in chromophobe carcinoma (82%) and oncocytoma (100%), whereas none of the cases of clear cell carcinomas were immunoreactive.
  • Cytokeratin 7 was positive in 18 (86%) of 22 cases of chromophobe carcinoma, whereas all oncocytomas were negative for CK7.
  • EpCAM protein was expressed in all 22 cases of chromophobe carcinoma in more than 90% of cells, whereas all EpCAM-positive oncocytomas (5/17; 29%) displayed positivity in single cells or small cell clusters.
  • CONCLUSIONS: Using the combination of 3 markers (vimentin, GST-alpha, and EpCAM), we achieved 100% sensitivity and 100% specificity for the differential diagnosis of chromophobe carcinoma, oncocytoma, and clear cell carcinoma.
  • The pattern of "vimentin(-)/GST-alpha(-)" effectively excluded clear cell carcinoma, and homogeneous EpCAM expression confirmed the diagnosis of chromophobe carcinoma rather than oncocytoma.
  • CD117 and CK7 were also useful markers and could be used as second-line markers for the differential diagnosis, with high specificity (100%) and high sensitivity (90% and 86%, respectively).
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Adenoma, Oxyphilic / diagnosis. Biomarkers, Tumor / analysis. Carcinoma, Renal Cell / diagnosis. Immunoenzyme Techniques / methods. Kidney Neoplasms / diagnosis. Neoplasm Proteins / analysis
  • [MeSH-minor] Diagnosis, Differential. Fluorescent Antibody Technique, Indirect. Humans. Predictive Value of Tests


58. Kajiyama H, Shibata K, Suzuki S, Ino K, Yamamoto E, Mizuno K, Sakakibara K, Matsuzawa K, Takeda A, Kinoshita Y, Kawai M, Nagasaka T, Nawa A, Kikkawa F: Is there any possibility of fertility-sparing surgery in patients with clear-cell carcinoma of the ovary? Gynecol Oncol; 2008 Dec;111(3):523-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there any possibility of fertility-sparing surgery in patients with clear-cell carcinoma of the ovary?
  • BACKGROUND: In epithelial ovarian cancer (EOC), fertility-sparing surgery (FSS) has mainly been chosen for stage IA disease.
  • The purpose of this study was to clarify the clinical outcome of patients with clear-cell carcinoma of the ovary (CCC) who would usually undergo radical surgery.
  • Nine patients were alive and one patient with stage IC(2) died of the disease at a follow-up time of 36.8 months.
  • [MeSH-major] Adenocarcinoma, Clear Cell / surgery. Fertility. Ovarian Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18538833.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  •  go-up   go-down


59. Cozar JM, Aptsiauri N, Tallada M, Garrido F, Ruiz-Cabello F: Late pulmonary metastases of renal cell carcinoma immediately after post-transplantation immunosuppressive treatment: a case report. J Med Case Rep; 2008;2:111
Repositorio Institucional de Salud de Andalucia. Full Text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late pulmonary metastases of renal cell carcinoma immediately after post-transplantation immunosuppressive treatment: a case report.
  • INTRODUCTION: We report a case of pulmonary metastatic recurrence of renal adenocarcinoma soon after radical nephrectomy that was followed by renal transplant and immunosuppressive medication.
  • Increased risk of metastatic recurrence of renal cell carcinoma should be considered in the immediate post-transplant period when immunosuppressive medication is administered, even if nephrectomy had been performed many years earlier.
  • In 1992 he underwent left side radical nephrectomy with histopathological diagnosis of clear cell adenocarcinoma.
  • CONCLUSION: Recurrence of renal cell carcinoma metastases points to tumor dormancy and reflects a misbalance between effective tumor immune surveillance and immune escape.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BJU Int. 1999 Sep;84(4):405-11 [10468753.001]
  • [Cites] J Urol. 1998 Apr;159(4):1163-7 [9507823.001]
  • [Cites] Nat Immunol. 2002 Nov;3(11):999-1005 [12407407.001]
  • [Cites] Surg Today. 2003;33(5):395-8 [12734740.001]
  • [Cites] Jpn J Clin Oncol. 2004 Jan;34(1):46-9 [15020663.001]
  • [Cites] J Urol. 2004 Jul;172(1):58-62 [15201737.001]
  • [Cites] JAMA. 2004 Jul 7;292(1):97-100 [15238597.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):251-7 [15593084.001]
  • [Cites] Curr Urol Rep. 2005 Feb;6(1):7-18 [15610692.001]
  • [Cites] Am J Transplant. 2005 Dec;5(12):3015-8 [16303018.001]
  • [Cites] Int J Urol. 2006 Apr;13(4):431-2 [16734864.001]
  • [Cites] Rev Urol. 2006 Winter;8(1):1-7 [16985554.001]
  • [Cites] Int J Urol. 2006 Dec;13(12):1525-7 [17118029.001]
  • [Cites] Int Rev Cytol. 2007;256:139-89 [17241907.001]
  • [Cites] Curr Opin Immunol. 2007 Apr;19(2):203-8 [17292599.001]
  • [Cites] Nat Rev Cancer. 2007 Nov;7(11):834-46 [17957189.001]
  • [Cites] J Urol. 1981 Jul;126(1):17-23 [7253072.001]
  • [Cites] J Theor Biol. 1994 Aug 21;169(4):327-38 [7967626.001]
  • [Cites] Nat Med. 1997 May;3(5):505-9 [9142117.001]
  • [Cites] Adv Ren Replace Ther. 2000 Apr;7(2):147-56 [10782732.001]
  • (PMID = 18423038.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2359763
  •  go-up   go-down


60. Ji SP, Li Q, Dong H: Therapy and prognostic features of primary clear cell carcinoma of the liver. World J Gastroenterol; 2010 Feb 14;16(6):764-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy and prognostic features of primary clear cell carcinoma of the liver.
  • AIM: To clarify the therapeutic strategies and prognosis factors of primary clear cell carcinoma of the liver (PCCCL).
  • Meanwhile, the PCCCL patients were subdivided into two subgroups on the basis of the proportion of clear cells in the tumor for pathological analysis.
  • There were 36 cases in subgroup A for which the proportion of clear cells was more than 70%, and 28 cases in subgroup B for which the proportion was less or equal to 70%, comparing analysis of median survival time of the counterpart groups.
  • The Kaplan-Meier method showed that capsule formation, preoperative liver function, hepatitis C virus infection, large vascular invasion and multiple tumor occurrences were related to disease-free survival.
  • Cox regression analysis showed that the clear cell ratio, capsule formation, preoperative liver function and large vascular invasion were independent risk factors for overall survival.
  • Clear cell ratio, capsule formation, preoperative liver function, and vascular invasion were independent risk factors for prognosis.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / surgery. Leucovorin / therapeutic use. Liver Neoplasms / drug therapy. Liver Neoplasms / surgery. Tegafur / therapeutic use

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):177-82 [10680884.001]
  • [Cites] World J Gastroenterol. 2008 Mar 21;14(11):1652-6 [18350595.001]
  • [Cites] Histopathology. 2001 Mar;38(3):225-31 [11260303.001]
  • [Cites] Kaohsiung J Med Sci. 2004 Feb;20(2):78-82 [15481555.001]
  • [Cites] Cancer. 1979 Nov;44(5):1677-83 [227575.001]
  • [Cites] Pathologica. 1994 Jun;86(3):307-10 [7808805.001]
  • [Cites] Pathol Int. 1996 Jul;46(7):503-9 [8870006.001]
  • [Cites] Dig Dis Sci. 1998 Jan;43(1):33-8 [9508531.001]
  • [Cites] Oncogene. 1999 Jan 7;18(1):181-7 [9926933.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2005;12(2):155-8 [15868082.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2005 May;4(2):306-7 [15908336.001]
  • [Cites] World J Surg. 2006 Mar;30(3):439-45 [16479331.001]
  • [Cites] Hepatogastroenterology. 2006 Jan-Feb;53(67):128-32 [16506391.001]
  • [Cites] Oncogene. 2006 Jun 26;25(27):3866-84 [16799628.001]
  • [Cites] World J Surg. 2007 Jun;31(6):1243-8 [17440771.001]
  • [Cites] World J Gastroenterol. 2008 Jan 7;14(1):129-31 [18176975.001]
  • [Cites] Liver Int. 2008 Feb;28(2):175-88 [18251977.001]
  • [Cites] Mod Pathol. 2000 Aug;13(8):874-81 [10955454.001]
  • (PMID = 20135727.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 1548R74NSZ / Tegafur; Q573I9DVLP / Leucovorin
  • [Other-IDs] NLM/ PMC2817067
  •  go-up   go-down


61. Mazouzi A, Benjelloun H, Benchekroun N, Acharki A, Benider A: [Clear cell carcinoma of the parotid gland]. Ann Otolaryngol Chir Cervicofac; 2005 Jun;122(3):142-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clear cell carcinoma of the parotid gland].
  • [Transliterated title] Carcinome à cellules claires de la glande parotide.
  • OBJECTIVES: Clear cell carcinomas of the parotid gland are hardly reported only fifty cases are known.
  • They are characterized by a proliferation of acinic epithelial cells and of clear myo epithelial cells.
  • The diagnosis was established by the parotid biopsy in 2 cases and after surgery in the third case.
  • It resulted in stabilization of the disease and a receding of 22 months for one patient and no trace of the second one because of a loss of the evolutionary pursuit.
  • CONCLUSION: With an in-depth analysis we can notice that clear cell carcinomas of the parotid gland are rare and mostly occur to old patients.
  • Radiation therapy linked to surgery seems to improve the local control of the disease.
  • [MeSH-major] Adenocarcinoma, Clear Cell / surgery. Parotid Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142093.001).
  • [ISSN] 0003-438X
  • [Journal-full-title] Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Société d'oto-laryngologie des hôpitaux de Paris
  • [ISO-abbreviation] Ann Otolaryngol Chir Cervicofac
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


62. Matsuura Y, Robertson G, Marsden DE, Kim SN, Gebski V, Hacker NF: Thromboembolic complications in patients with clear cell carcinoma of the ovary. Gynecol Oncol; 2007 Feb;104(2):406-10
MedlinePlus Health Information. consumer health - Pulmonary Embolism.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thromboembolic complications in patients with clear cell carcinoma of the ovary.
  • OBJECTIVE: The purpose of this study was to define the incidence of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients with clear cell carcinoma (CCC) of the ovary and to investigate the prognostic factors in such patients.
  • Sixty-six patients (10.3%) with CCC were identified from the data bank, and their data were compared with a matched-control group of 132 patients with non-clear cell epithelial ovarian carcinoma.
  • In a multivariate analysis of patients matched for age and stage, the occurrence of a DVT or the presence of endometriosis was significant predictors of clear cell histology.
  • Within the clear cell group, no particular risk factor for DVT could be identified.
  • [MeSH-major] Adenocarcinoma, Clear Cell / complications. Ovarian Neoplasms / complications. Pulmonary Embolism / etiology. Venous Thrombosis / etiology

  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17014897.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Kato N, Motoyama T: Overexpression of osteopontin in clear cell carcinoma of the ovary: close association with HNF-1beta expression. Histopathology; 2008 May;52(6):682-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of osteopontin in clear cell carcinoma of the ovary: close association with HNF-1beta expression.
  • AIMS: Transcription factor hepatocyte nuclear factor (HNF)-1beta is selectively expressed in clear cell carcinoma (CCC) of the ovary.
  • METHODS AND RESULTS: Three CCC and two serous adenocarcinoma (SA) cell lines were evaluated for expression of OPN by reverse transcriptase-polymerase chain reaction and immunocytochemistry.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Hepatocyte Nuclear Factor 1-beta / metabolism. Osteopontin / metabolism. Ovarian Neoplasms / metabolism. Ovary / metabolism
  • [MeSH-minor] Cell Line, Tumor. Female. Gene Expression. Humans. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18393978.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 106441-73-0 / Osteopontin; 138674-15-4 / Hepatocyte Nuclear Factor 1-beta
  •  go-up   go-down


64. Hu YJ, Ip PP, Chan KK, Tam KF, Ngan HY: Ovarian clear cell carcinoma with choriocarcinomatous differentiation: report of a rare and aggressive tumor. Int J Gynecol Pathol; 2010 Nov;29(6):539-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian clear cell carcinoma with choriocarcinomatous differentiation: report of a rare and aggressive tumor.
  • Ovarian epithelial tumors of nongerm cell origin with true choriocarcinomatous differentiation are rare.
  • In the reported cases, the epithelial component was of mixed cell types or of mucinous differentiation.
  • To the best of our knowledge, an ovarian carcinoma exclusively of clear cell differentiation coexisting with a pure choriocarcinoma has not been reported earlier.
  • Trucut biopsy of the mass showed a poorly differentiated carcinoma that was immunoreactive for CK7 and hCG.
  • Pathologic examination showed an ovarian clear cell carcinoma with a second component of choriocarcinoma in which the bilaminar growth pattern of cytotrophoblast and syncytiotrophoblasts was striking.
  • Despite additional therapy, which included 2 cycles of TE/TP and 2 cycles of gemcitabine/taxotere, the disease progressed and the patient died 11 months postoperatively.
  • This report showed that ovarian clear cell carcinoma with choriocarcinomatous differentiation is a highly aggressive tumor and has a very poor prognosis.
  • Nonetheless, there may be a role for neoadjuvant chemotherapy that targets both the clear cell and the choriocarcinoma components to reduce the volume of the disease before debulking surgery.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Choriocarcinoma, Non-gestational / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20881859.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


65. Takami M, Ohta Y, Nakayama Y, Fukai H, Matsumoto H, Takimoto T, Sakamoto H, Yamamoto T: [A case of advanced clear cell carcinoma of the endometrium that responded remarkably to neoadjuvant chemotherapy of combination carboplatin plus weekly paclitaxel]. Gan To Kagaku Ryoho; 2007 Mar;34(3):457-60
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced clear cell carcinoma of the endometrium that responded remarkably to neoadjuvant chemotherapy of combination carboplatin plus weekly paclitaxel].
  • Clear cell carcinoma of the endometrium is a very rare and highly malignant neoplasm that accounts for less than 5% of endometrial carcinoma.
  • Survival of patients in the advanced stage is poor, and the treatment of choice is not clear.
  • We report the case of a 62-year-old woman who had Stage IVb advanced clear cell carcinoma of the endometrium with multiple lung metastases.
  • The current case suggests that combination CBDCA plus weekly PTX is effective against advanced clear cell carcinoma of the endometrium.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endometrial Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17353643.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


66. Suzuki H, Yamauchi G, Hashimoto K: Clear cell carcinoma of the mandibular gingiva 'minor salivary gland': a case report with immunohistochemical study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Mar;103(3):e36-40
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma of the mandibular gingiva 'minor salivary gland': a case report with immunohistochemical study.
  • Clear cell carcinoma is a rare neoplasm that arises in salivary glands.
  • Initial clinical diagnosis was squamous cell carcinoma based on this erythroplakial lesion.
  • This report examined the immunohistochemical characteristics of clear cell carcinoma, minor salivary gland, and reviewed the existing literature.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Gingival Neoplasms / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17321437.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 68238-35-7 / Keratins
  • [Number-of-references] 14
  •  go-up   go-down


67. Shibata K, Kajiyama H, Mizokami Y, Ino K, Nomura S, Mizutani S, Terauchi M, Kikkawa F: Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia. Gynecol Oncol; 2005 Jul;98(1):11-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia.
  • OBJECTIVE: Increased glucose consumption is a characteristic of malignant cells.
  • Glucose is transported into the cell via facilitative glucose transporters, which are known to be members of a supergene family.
  • P-LAP is a cell surface aminopeptidase, and is a synonym for oxytocinase.
  • The authors evaluated P-LAP and GLUT4 expression in benign, borderline, and malignant ovarian epithelia.
  • METHODS: Histologic sections of formalin-fixed, paraffin-embedded specimens from 11 patients with benign serous or mucinous cystadenomas, 14 patients with serous or mucinous borderline tumors, and 80 patients with epithelial-ovarian adenocarcinomas (29 serous, 17 endometrioid, 14 mucinous, and 20 clear cell adenocarcinomas) were stained for P-LAP and GLUT4 using each polyclonal antibody.
  • P-LAP was expressed in 23 of 29 in serous, 15 of 17 endometrioid, 13 of 14 mucinous, and all clear-cell adenocarcinomas.
  • The tendency toward increased P-LAP expression with advancing grade was observed in serous adenocarcinomas.
  • GLUT4 was expressed in 13 of 29 serous, 13 of 17 endometrioid, 13 of 14 mucinous, and 18 of 20 clear-cell adenocarcinomas.
  • In invasive carcinomas, there was a direct correlation between P-LAP immunoreactivity and GLUT4 immunoreactivity (correlation coefficient [r] = 0.58; P < 0.01).
  • Further study to investigate the roles of P-LAP and GLUT4 in ovarian carcinoma is needed.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Growth Processes / physiology. Cell Line, Tumor. Epithelium / enzymology. Epithelium / metabolism. Female. Glucose Transporter Type 4. Humans. Middle Aged. Neoplasm Invasiveness. Ovarian Diseases / enzymology. Ovarian Diseases / metabolism. Ovarian Diseases / pathology. Transfection

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15907336.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucose Transporter Type 4; 0 / Monosaccharide Transport Proteins; 0 / Muscle Proteins; 0 / SLC2A4 protein, human; EC 3.4.11.3 / Cystinyl Aminopeptidase; EC 3.4.11.3 / leucyl-cystinyl aminopeptidase
  •  go-up   go-down


68. Umezu T, Shibata K, Kajiyama H, Yamamoto E, Nawa A, Kikkawa F: Glypican-3 expression predicts poor clinical outcome of patients with early-stage clear cell carcinoma of the ovary. J Clin Pathol; 2010 Nov;63(11):962-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glypican-3 expression predicts poor clinical outcome of patients with early-stage clear cell carcinoma of the ovary.
  • BACKGROUND: Glypican-3 (GPC3), a membrane-bound heparan sulphate proteoglycan, may play a role in promoting cancer cell growth and differentiation.
  • Recent studies reported that GPC3 is overexpressed in clear cell carcinoma (CCC) of the ovary, and not other ovarian histotypes.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Biomarkers, Tumor / metabolism. Glypicans / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Bridged Compounds / therapeutic use. Cell Proliferation. Drug Resistance, Neoplasm. Female. Humans. Middle Aged. Neoplasm Proteins / metabolism. Neoplasm Staging. Prognosis. Survival Analysis. Taxoids / therapeutic use. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20972242.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Bridged Compounds; 0 / GPC3 protein, human; 0 / Glypicans; 0 / Neoplasm Proteins; 0 / Taxoids; 1605-68-1 / taxane
  •  go-up   go-down


69. Umezu T, Shibata K, Shimaoka M, Kajiyama H, Yamamoto E, Ino K, Nawa A, Senga T, Kikkawa F: Gene silencing of glypican-3 in clear cell carcinoma of the ovary renders it more sensitive to the apoptotic agent paclitaxel in vitro and in vivo. Cancer Sci; 2010 Jan;101(1):143-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene silencing of glypican-3 in clear cell carcinoma of the ovary renders it more sensitive to the apoptotic agent paclitaxel in vitro and in vivo.
  • Glypican-3 (GPC3) is a heparan sulfate proteoglycan that is bound to the cell membrane by a glycosylphosphatidylinositol (GPI) anchor, and glypicans can regulate the activity of a wide variety of growth and survival factors.
  • We report here that GPC3 was expressed in clear cell carcinoma of the ovary, and not in other carcinomas.
  • To evaluate the phenotype and potential preclinical relevance, we generated an ovarian cancer cell line stably transfected with plasmids encompassing shRNA targeting GPC3.
  • We show that the clear cell carcinoma cell line with silenced GPC3 expression (GPC3 [-]) was more sensitive to paclitaxel than GPC3 (+) cells.
  • These results indicate that increased GPC3 expression in a clear cell carcinoma cell line may play a protective role against apoptosis, and so the downregulation of GPC3 may be a potential target to increase sensitivity to paclitaxel-induced apoptosis in clear cell carcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Apoptosis / drug effects. Glypicans / antagonists & inhibitors. Ovarian Neoplasms / drug therapy. Paclitaxel / pharmacology
  • [MeSH-minor] Animals. Base Sequence. Cell Line, Tumor. Female. Gene Silencing. Humans. Mice. Molecular Sequence Data

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19860840.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glypicans; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


70. Rust MM, Susa J, Naylor R, Cavuoti D: Clear cell carcinoma in a background of endometriosis. Case report of a finding in a midline abdominal scar 5 years after a total abdominal hysterectomy. Acta Cytol; 2008 Jul-Aug;52(4):475-80
MedlinePlus Health Information. consumer health - Scars.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma in a background of endometriosis. Case report of a finding in a midline abdominal scar 5 years after a total abdominal hysterectomy.
  • BACKGROUND: Endometriosis is considered a premalignant process whose association with carcinoma is well documented.
  • We discuss a case of clear cell carcinoma with an unusual presentation in that it was located outside the abdominal cavity and was the only lesion noted clinically and radiologically.
  • The histopathologic diagnostic criteria will be reviewed, as will the association of carcinomas with endometriosis.
  • Furthermore, we will review the current literature of extraovarian clear cell carcinoma associated with endometriosis with regard to clinical outcome.
  • The FNA sample was reported as highly atypical cells suspicious for adenocarcinoma.
  • Excision of this mass revealed a clear cell carcinoma in a background of endometriosis.
  • CONCLUSION: Clear cell carcinoma is one of the most prevalent carcinomas associated with endometriosis, whether identified in the ovary or extraovarian site.
  • [MeSH-major] Abdominal Wall / pathology. Carcinoma / etiology. Cicatrix / pathology. Endometriosis / complications. Hysterectomy / adverse effects. Soft Tissue Neoplasms / etiology

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18702369.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 22
  •  go-up   go-down


71. Takano M, Sugiyama T, Yaegashi N, Suzuki M, Tsuda H, Sagae S, Udagawa Y, Kuzuya K, Kigawa J, Takeuchi S, Tsuda H, Moriya T, Kikuchi Y: Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis. Int J Clin Oncol; 2007 Aug;12(4):256-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis.
  • BACKGROUND: Irinotecan hydrochloride, a topoisomerase I inhibitor, has been preliminarily recognized as an effective agent against clear cell carcinoma of the ovary (CCC), but there are few clinical data.
  • METHODS: One hundred and seventeen patients at International Federation of Gynecology and Obstetrics (FIGO) stages Ic (ascites/malignant washing) - IV were identified by scanning the medical records of ten Japanese hospitals.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Carboplatin / therapeutic use. Cisplatin / therapeutic use. Ovarian Neoplasms / drug therapy. Paclitaxel / therapeutic use
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Middle Aged. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17701003.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


72. Bjørge T, Engeland A, Tretli S, Weiderpass E: Body size in relation to cancer of the uterine corpus in 1 million Norwegian women. Int J Cancer; 2007 Jan 15;120(2):378-83
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It has been hypothesized that obesity is mostly associated with a subtype described as estrogen-dependent (Type I tumors), constituting about 80% of the endometrial tumors.
  • The tumors were classified as Type I tumors (mostly endometrial adenocarcinomas with subgroups), Type II tumors (papillary, serous, and clear cell adenocarcinomas and some poorly differentiated carcinomas), sarcomas, and mixed tumors.
  • The increase in risk was most pronounced for Type I tumors, but was also seen for Type II tumors, sarcomas and mixed tumors.
  • The overall RR of corpus uteri cancer associated with a 10-cm increase in height was 1.09 (95% CI: 1.05-1.13), and was mostly observed for Type I tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 17066451.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Allende DS, Drake RD, Chen L: Mural nodules of clear cell carcinoma in a mucinous borderline tumor of the ovary: a case report. Patholog Res Int; 2010;2010:438534

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mural nodules of clear cell carcinoma in a mucinous borderline tumor of the ovary: a case report.
  • In this study, we report a case of mural nodules of clear cell carcinoma in an intestinal type mucinous borderline tumor of the ovary.
  • Microscopic examination revealed that the cystic mass was an intestinal type borderline mucinous tumor.
  • The mural nodules showed a classic histology of clear cell carcinoma with tubulocystic and papillary growth patterns.
  • This is an extremely rare case of mural nodules of clear cell carcinoma arising in a mucinous borderline tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21151689.001).
  • [ISSN] 2042-003X
  • [Journal-full-title] Pathology research international
  • [ISO-abbreviation] Patholog Res Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2991063
  •  go-up   go-down


74. Dionigi G, Uccella S, Gandolfo M, Lai A, Bertocchi V, Rovera F, Tanda ML: Solitary intrathyroidal metastasis of renal clear cell carcinoma in a toxic substernal multinodular goiter. Thyroid Res; 2008;1(1):6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary intrathyroidal metastasis of renal clear cell carcinoma in a toxic substernal multinodular goiter.
  • She had a history of renal clear cell carcinoma of the left kidney, which had been resected 2 years previously.
  • A histological examination revealed a solitary metastasis of a clear cell renal cancer in a diffuse multinodular goiter.
  • The diagnosis can be suspected if the patient has a thyroid tumor and a past history of extrathyroid cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr J. 2008 May;55(2):359-64 [18379125.001]
  • [Cites] Thyroid. 1999 Dec;9(12):1273-80 [10646671.001]
  • [Cites] Thyroid. 2008 Jan;18(1):85-7 [17887930.001]
  • [Cites] World J Surg. 2007 May;31(5):879-87 [17308849.001]
  • [Cites] Eur J Surg Oncol. 2007 Feb;33(1):83-5 [17085008.001]
  • [Cites] Langenbecks Arch Surg. 2006 Nov;391(6):581-7 [16983577.001]
  • [Cites] Eur J Endocrinol. 2006 Jun;154(6):787-803 [16728537.001]
  • [Cites] Hum Pathol. 2005 Jun;36(6):698-701 [16021578.001]
  • [Cites] Ann Surg. 1960 Apr;151:551-61 [13820008.001]
  • [Cites] Cancer. 1956 Mar-Apr;9(2):306-9 [13304848.001]
  • [Cites] Ann Surg. 1964 Aug;160:169-77 [14209716.001]
  • [Cites] Cancer. 1962 May-Jun;15:557-65 [13911946.001]
  • [Cites] AMA Arch Pathol. 1955 Mar;59(3):291-311 [14349472.001]
  • [Cites] World J Surg. 1999 Feb;23(2):177-80; discussion 181 [9880428.001]
  • [Cites] Thyroid. 1998 Feb;8(2):149-53 [9510123.001]
  • [Cites] Am J Clin Pathol. 1998 Mar;109(3):294-301 [9495201.001]
  • [Cites] Arch Pathol Lab Med. 1998 Jan;122(1):37-41 [9448014.001]
  • [Cites] Cancer. 1997 Feb 1;79(3):574-8 [9028370.001]
  • [Cites] Ann Surg Oncol. 1995 May;2(3):252-6 [7641022.001]
  • [Cites] Endocrinol Metab Clin North Am. 1990 Sep;19(3):637-48 [2261909.001]
  • [Cites] Cancer. 1989 May 1;63(9):1810-5 [2649228.001]
  • [Cites] Tumori. 1987 Apr 30;73(2):187-90 [3554676.001]
  • [Cites] Mayo Clin Proc. 1984 Dec;59(12):856-9 [6503368.001]
  • [Cites] Pathol Res Pract. 1985 May;179(6):666-72 [4022843.001]
  • [Cites] Surg Gynecol Obstet. 1982 Oct;155(4):503-5 [7123465.001]
  • [Cites] Cancer. 1981 Sep 15;48(6):1487-91 [7272969.001]
  • [Cites] Acta Otolaryngol. 1969 May;67(5):552-62 [5378598.001]
  • [Cites] J Pathol. 1974 May;113(1):21-5 [4412457.001]
  • [Cites] Eur J Surg Oncol. 2004 Aug;30(6):583-8 [15256229.001]
  • [Cites] Thyroid. 2004 Jan;14(1):65-70 [15009916.001]
  • [Cites] Cancer. 2002 Nov 1;95(9):1869-78 [12404280.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Oct;57(4):551-6 [12354139.001]
  • [Cites] Surg Today. 2002;32(2):151-4 [11998944.001]
  • [Cites] Cancer. 2000 Mar 1;88(5):1149-58 [10699906.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2008 Apr;16(2):158-62 [18327036.001]
  • (PMID = 19014412.001).
  • [ISSN] 1756-6614
  • [Journal-full-title] Thyroid research
  • [ISO-abbreviation] Thyroid Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2596782
  •  go-up   go-down


75. Lee HY, Lee DG, Chun K, Lee S, Song SY: Clear cell carcinoma of the pancreas--a case report and review of the literature. Cancer Res Treat; 2009 Sep;41(3):175-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma of the pancreas--a case report and review of the literature.
  • Most of the malignant neoplasms of the pancreas demonstrate features that are consistent with adenocarcinoma.
  • According to the WHO classification, primary clear cell carcinoma of the pancreas is rare and it is classified as a "miscellaneous" carcinoma.
  • We report here on an unusual case of primary pancreatic clear cell carcinoma, which is the first such reported case in Korea.
  • On the abdominal computed tomography (CT), we detected an abdominal mass involving the pancreas tail and liver, and clear cell carcinoma with rhabdoid feature was seen on the histologic evaluation.
  • The tumor cells showed well defined cell membranes, clear cytoplasm and prominent cell boundaries.
  • She was diagnosed with a primary pancreatic clear cell carcinoma with hepatic metastasis and she received palliative gemcitabine chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2008 Sep;21(9):1075-83 [18536653.001]
  • [Cites] JOP. 2007;8(3):330-4 [17495363.001]
  • [Cites] Histopathology. 1998 May;32(5):444-8 [9639120.001]
  • [Cites] Semin Diagn Pathol. 1997 Aug;14(3):213-9 [9279977.001]
  • [Cites] Semin Diagn Pathol. 1997 Aug;14(3):183-202 [9279975.001]
  • [Cites] Ann Diagn Pathol. 2002 Dec;6(6):381-4 [12478490.001]
  • [Cites] Arch Pathol Lab Med. 1989 Feb;113(2):113-4 [2916901.001]
  • [Cites] Acta Pathol Jpn. 1987 Sep;37(9):1521-6 [3687432.001]
  • [Cites] Arch Pathol Lab Med. 2004 Jun;128(6):693-6 [15163226.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(2):140-4 [15127279.001]
  • [Cites] Gastroenterology. 1991 Jan;100(1):233-8 [1983826.001]
  • (PMID = 19809568.001).
  • [ISSN] 1598-2998
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2757667
  • [Keywords] NOTNLM ; Clear cell carcinoma / Pancreas / Rhabdoid tumor
  •  go-up   go-down


76. Kajiyama H, Hosono S, Terauchi M, Shibata K, Ino K, Yamamoto E, Nomura S, Nawa A, Kikkawa F: Twist expression predicts poor clinical outcome of patients with clear cell carcinoma of the ovary. Oncology; 2006;71(5-6):394-401
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Twist expression predicts poor clinical outcome of patients with clear cell carcinoma of the ovary.
  • We examined the distribution and expression of this molecule in clear cell carcinoma of the ovary (CCC) to elucidate their clinical significance.
  • RESULTS: In the 27 carcinomas, negative Twist immunoexpression was observed in 14 cases (51.9%), and positive immunoexpression in 13 (48.1%).
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Biomarkers, Tumor / biosynthesis. Ovarian Neoplasms / diagnosis. Twist Transcription Factor / biosynthesis
  • [MeSH-minor] Adult. Aged. Cell Line, Tumor. Disease Progression. Disease-Free Survival. Female. Humans. Middle Aged. Multivariate Analysis. Predictive Value of Tests. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 17690559.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Twist Transcription Factor
  •  go-up   go-down


77. Lao XM, Zhang YQ, Jin X, Lin XJ, Guo RP, Li GH, Li JQ: Primary clear cell carcinoma of liver--clinicopathologic features and surgical results of 18 cases. Hepatogastroenterology; 2006 Jan-Feb;53(67):128-32
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary clear cell carcinoma of liver--clinicopathologic features and surgical results of 18 cases.
  • BACKGROUND/AIMS: Primary clear cell carcinoma of the liver (PCCCL) is a subgroup of hepatocellular carcinoma.
  • RESULTS: Histological examinations showed PCCCL was characterized by large numbers of vacuolated clear cells.
  • CONCLUSIONS: The clear cells of PCCCL contain substantial quantities of glycogen and lipid.
  • The clinical characteristics of the PCCCL are similar to those of conventional hepatocellular carcinoma.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / surgery. Liver Neoplasms / pathology. Liver Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16506391.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


78. Vera-Alvarez J, García-Prats MD, Marigil-Gómez M, Abascal-Agorreta M, López-López JI, Ramón-Cajal JM: Clear cell carcinoma of the ovary diagnosed in ascitic fluid. A case report. Acta Cytol; 2007 Jan-Feb;51(1):107-12
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma of the ovary diagnosed in ascitic fluid. A case report.
  • BACKGROUND: Clear cell carcinoma of the ovary (CCC) is a rare variety of ovarian cancer.
  • Peritoneal fluid cytology revealed papillary clusters of cells with clear cytoplasm and extracellular hyaline material generally without neoplastic cells.
  • The tumor was excised, and the histologic sections confirmed the cytologic diagnosis.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Ascites / etiology. Ascites / pathology. Ovarian Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17328509.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Mabuchi S, Kawase C, Altomare DA, Morishige K, Sawada K, Hayashi M, Tsujimoto M, Yamoto M, Klein-Szanto AJ, Schilder RJ, Ohmichi M, Testa JR, Kimura T: mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res; 2009 Sep 1;15(17):5404-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary.
  • PURPOSE: Mammalian target of rapamycin (mTOR) plays a central role in cell proliferation and is regarded as a promising target in cancer therapy, including for ovarian cancer.
  • This study aimed to examine the role of mTOR as a therapeutic target in clear cell carcinoma of the ovary, which is regarded as an aggressive, chemoresistant histologic subtype.
  • EXPERIMENTAL DESIGN: Using tissue microarrays of 98 primary ovarian cancers (52 clear cell carcinomas and 46 serous adenocarcinomas), the expression of phospho-mTOR was assessed by immunohistochemistry.
  • Then, the growth-inhibitory effect of mTOR inhibition by RAD001 (everolimus) was examined using two pairs of cisplatin-sensitive parental (RMG1 and KOC7C) and cisplatin-resistant human clear cell carcinoma cell lines (RMG1-CR and KOC7C-CR) both in vitro and in vivo.
  • RESULTS: Immunohistochemical analysis showed that mTOR was more frequently activated in clear cell carcinomas than in serous adenocarcinomas (86.6% versus 50%).
  • CONCLUSION: mTOR is frequently activated in clear cell carcinoma and can be a promising therapeutic target in the management of clear cell carcinoma.
  • Moreover, mTOR inhibition by RAD001 may be efficacious as a second-line treatment of recurrent disease in patients previously treated with cisplatin.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2004 Jun;10(6):594-601 [15156201.001]
  • [Cites] Gynecol Oncol. 2008 Sep;110(3):336-44 [18639330.001]
  • [Cites] Oncogene. 2004 Jul 29;23(34):5853-7 [15208673.001]
  • [Cites] Gynecol Oncol. 2004 Sep;94(3):643-9 [15350353.001]
  • [Cites] Cancer Res. 1987 Jan 15;47(2):414-8 [3539322.001]
  • [Cites] J Biol Chem. 1998 Feb 27;273(9):5315-22 [9478990.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7418-26 [15534119.001]
  • [Cites] Cell. 2005 Mar 25;120(6):747-59 [15797377.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7052-8 [16103051.001]
  • [Cites] Mol Cancer Ther. 2005 Oct;4(10):1533-40 [16227402.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16(1):52-6 [16445610.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1500-8 [16452206.001]
  • [Cites] Gynecol Oncol. 2006 Apr;101(1):71-5 [16290000.001]
  • [Cites] Endocrinology. 2006 Apr;147(4):1761-9 [16396982.001]
  • [Cites] Br J Cancer. 2006 May 22;94(10):1369-74 [16641903.001]
  • [Cites] Gynecol Oncol. 2006 Aug;102(2):292-9 [16443261.001]
  • [Cites] Gynecol Oncol. 2006 Aug;102(2):285-91 [16516283.001]
  • [Cites] J Surg Oncol. 2006 Aug 1;94(2):138-43 [16847906.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jul-Aug;16(4):1545-51 [16884363.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2584-9 [10861437.001]
  • [Cites] Cell. 2000 Oct 13;103(2):253-62 [11057898.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):5988-94 [11085518.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1862-8 [11280739.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10314-9 [11504908.001]
  • [Cites] Nat Rev Cancer. 2002 Jul;2(7):489-501 [12094235.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2448-54 [12114452.001]
  • [Cites] J Biol Chem. 2002 Sep 6;277(36):33490-500 [12087097.001]
  • [Cites] Mol Cell. 2003 Jun;11(6):1491-501 [12820963.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3194-200 [12860964.001]
  • [Cites] Gynecol Oncol. 2003 Oct;91(1):123-9 [14529671.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):252-61 [14729632.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):1013-23 [14871980.001]
  • [Cites] J Biol Chem. 2004 May 28;279(22):23477-85 [15026414.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2408-13 [17363557.001]
  • [Cites] Oncogene. 2007 Mar 22;26(13):1932-40 [17001314.001]
  • [Cites] Gynecol Oncol. 2007 May;105(2):404-8 [17292461.001]
  • [Cites] Clin Cancer Res. 2007 Jul 15;13(14):4261-70 [17634556.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3621-7 [17704411.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Autophagy. 2008 May;4(4):467-75 [18259115.001]
  • [Cites] Lancet. 2008 Aug 9;372(9637):449-56 [18653228.001]
  • [Cites] Gynecol Oncol. 2004 Jul;94(1):197-203 [15262142.001]
  • (PMID = 19690197.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA06927; United States / NCI NIH HHS / CA / CA083638-10; United States / NCI NIH HHS / CA / CA077429-02; United States / NCI NIH HHS / CA / P30 CA006927-45; United States / NCI NIH HHS / CA / CA83638; United States / NCI NIH HHS / CA / R01 CA077429; United States / NCI NIH HHS / CA / P50 CA083638-10; United States / NCI NIH HHS / CA / P50 CA083638; United States / NCI NIH HHS / CA / R01 CA077429-02; United States / NCI NIH HHS / CA / CA77429; United States / NCI NIH HHS / CA / P30 CA006927
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents; 9HW64Q8G6G / Everolimus; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; Q20Q21Q62J / Cisplatin; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ NIHMS125079; NLM/ PMC2743856
  •  go-up   go-down


80. Pradhan M, Abeler VM, Danielsen HE, Tropé CG, Risberg BA: Image cytometry DNA ploidy correlates with histological subtypes in endometrial carcinomas. Mod Pathol; 2006 Sep;19(9):1227-35
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Image cytometry DNA ploidy correlates with histological subtypes in endometrial carcinomas.
  • Image cytometric DNA ploidy analysis of endometrial carcinomas was performed to determine whether ploidy status and ploidy-related parameters like DNA index, percentage of cells exceeding 5c and 9c, correlate with histologic subtype.
  • This is a prospective study of 391 patients with stage I endometrial carcinoma which included 331 (85%) endometrioid adenocarcinoma, 22 (6%) serous adenocarcinoma, 7 (2%) clear cell adenocarcinoma, 2 (0.5%) small cell carcinoma, 1 (0.3%) undifferentiated carcinoma, and 28 (7%) unclassifiable adenocarcinoma.
  • Twenty-five percent of endometrioid adenocarcinomas were non-diploid.
  • In contrast, all clear cell adenocarcinomas and 21/22 (95%) of serous adenocarcinomas were non-diploid.
  • Hyperdiploidy (25 cases) was found only in endometrioid adenocarcinomas.
  • Mean DNA index of the stemline in serous adenocarcinoma (1.72) and clear cell adenocarcinoma (1.81) was higher than in endometrioid adenocarcinoma (1.1).
  • The difference in ploidy-related parameters between endometrioid adenocarcinoma and serous adenocarcinoma was highly significant (P<0.001).
  • In addition, Grade 3 endometrioid adenocarcinoma showed significant difference in all ploidy-related parameters compared with grade 1 and grade 2 tumors (P<0.001).
  • Our results show that DNA ploidy-related parameters may be valuable in subtyping histologically difficult cases of endometrial carcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Aneuploidy. DNA, Neoplasm / analysis. Endometrial Neoplasms / genetics. Image Cytometry / methods
  • [MeSH-minor] Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / pathology. Cell Count. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / pathology. Female. Humans. Middle Aged. Neoplasm Staging. Prospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published online 26 May 2006.
  • (PMID = 16729014.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


81. Goto K, Takeuchi Y, Yakihara A, Kotsuji F: Synchronous invasive squamous cell carcinoma and clear cell adenocarcinoma of the uterine cervix: a different human papillomavirus status. Gynecol Oncol; 2005 Jun;97(3):976-9
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous invasive squamous cell carcinoma and clear cell adenocarcinoma of the uterine cervix: a different human papillomavirus status.
  • BACKGROUND: A multiple primary invasive carcinoma of the cervix is a rare condition and is seldom composed of squamous cell carcinoma and clear cell adenocarcinoma.
  • Preoperative pathological and imaging studies demonstrated the squamous cell carcinoma of the exocervix alone.
  • Radical hysterectomy was performed on the diagnosis of stage 1B cervical cancer.
  • Histological examination of the specimen manifested a coexisting invasive clear cell adenocarcinoma in the endocervix.
  • Human papillomavirus (HPV) 18 was detected in the squamous cell carcinoma; however, no HPV was detected in the clear cell adenocarcinoma.
  • CONCLUSION: This finding suggests that there was an obvious difference in association of HPV with the two neoplasms.
  • [MeSH-major] Adenocarcinoma, Clear Cell / virology. Carcinoma, Squamous Cell / virology. Neoplasms, Multiple Primary / virology. Papillomaviridae. Uterine Cervical Neoplasms / virology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15896829.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Dursun P, Gültekin M, Yüce K, Ayhan A: Skeletal carcinomatosis in endometrial clear cell carcinoma at initial presentation: a case report. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):891-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skeletal carcinomatosis in endometrial clear cell carcinoma at initial presentation: a case report.
  • To the best of our knowledge, this is the first report of a case with disseminated bone metastasis from endometrial clear cell carcinoma.
  • Diagnostic workup revealed endometrial clear cell carcinoma.
  • Bone metastasis in endometrial clear cell carcinoma may be seen at initial presentation and may involve multiple bones.
  • Further studies are needed to elucidate the true incidence and management of bone metastasis in endometrial clear cell carcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / secondary. Bone Neoplasms / secondary. Endometrial Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681779.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Hirabayashi K, Yasuda M, Osamura RY, Hirasawa T, Murakami M: Ovarian nongestational choriocarcinoma mixed with various epithelial malignancies in association with endometriosis. Gynecol Oncol; 2006 Jul;102(1):111-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The right ovary revealed a cystic tumor with two solid parts: larger part, endometrioid adenocarcinoma and small cell carcinoma; smaller part, predominantly CC and focally clear cell adenocarcinoma.
  • We assume that endometrioid and clear cell adenocarcinomas arose at different sites as tumorigenic factors in association with endometriosis, and the former may have been dedifferentiated into small cell carcinoma and the latter to CC.
  • Coexistence of CC with small cell carcinoma is considered to be responsible for relative chemoresistance leading to poor prognosis.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / complications. Adenocarcinoma, Clear Cell / pathology. Carcinoma, Endometrioid / complications. Carcinoma, Endometrioid / pathology. Carcinoma, Small Cell / complications. Carcinoma, Small Cell / pathology. Female. Humans. Middle Aged


84. Basely M, Bonnel S, Maszelin P, Verdalle P, Bussy E, de Jaureguiberry JP: A rare presentation of metastatic renal clear cell carcinoma to the tongue seen on FDG PET. Clin Nucl Med; 2009 Sep;34(9):566-9
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare presentation of metastatic renal clear cell carcinoma to the tongue seen on FDG PET.
  • Renal clear cell carcinoma has a great metastatic potential, with possibly uncommon secondary lesions, notably in the head and neck region.
  • We report a case of metastatic renal cell carcinoma involving the tongue and a cervical lymph node, 3 years after initial nephrectomy.
  • Although the diagnostic performance of F-18 FDG PET is limited in the detection of primary disease, this imaging modality can be a very useful tool in the follow-up of renal clear cell carcinoma.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / radionuclide imaging. Fluorodeoxyglucose F18. Kidney Neoplasms / pathology. Kidney Neoplasms / radionuclide imaging. Tongue Neoplasms / radionuclide imaging. Tongue Neoplasms / secondary

  • Genetic Alliance. consumer health - Clear Cell Renal Cell Carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19692815.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


85. Ryu SY, Park SI, Nam BH, Kim I, Yoo CW, Nam JH, Lee KH, Cho CH, Kim JH, Park SY, Kim BG, Kang SB: Prognostic significance of histological grade in clear-cell carcinoma of the ovary: a retrospective study of Korean Gynecologic Oncology Group. Ann Oncol; 2009 Jun;20(6):1032-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of histological grade in clear-cell carcinoma of the ovary: a retrospective study of Korean Gynecologic Oncology Group.
  • BACKGROUND: This study was to investigate the prognostic significance of clinicopathologic characteristics in patients with clear-cell carcinoma (CCC) of the ovary.
  • Early-stage disease showed a favorable prognosis, but advanced diseases showed poor prognosis.
  • Stage of disease was the only significant prognostic factor on multivariate analysis (P < 0.001).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19193704.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


86. Fujiu K, Miyamoto H, Hashimoto S, Suzuki N, Takano Y, Teranishi Y, Sakuma H, Suzuki H: A case of diaphragmatic clear cell carcinoma in a patient with a medical history of ovarian endometriosis. Int J Clin Oncol; 2010 Oct;15(5):489-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of diaphragmatic clear cell carcinoma in a patient with a medical history of ovarian endometriosis.
  • We present a case of clear cell carcinoma located in the diaphragm in a patient with a medical history of ovarian endometriosis.
  • Histopathological examination revealed the presence of clear cells and hobnail cells.
  • The clear cells contained pale or eosinophilic cytoplasm and were arranged in a solid pattern.
  • The findings were compatible with those of ovarian clear cell carcinoma.

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20221659.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


87. Yamashita K, Kawakami F, Nakashima Y, Murakami K: Clear cell carcinoma of the minor salivary gland: an autopsy case with multiple metastases 29 years after the initial surgery and a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Jun;107(6):819-25
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma of the minor salivary gland: an autopsy case with multiple metastases 29 years after the initial surgery and a review of the literature.
  • Clear cell carcinoma of the salivary gland is an uncommon tumor comprising about 1% of neoplasms of minor salivary glands.
  • Five years later, the patient died of widespread metastases of the disease at the age of 77.
  • Specimens obtained at the initial excision and at autopsy were very similar histologically and immunohistochemically, and both were clear cell carcinoma of the salivary gland.
  • The patient died of the disease after a very long disease-free period, which reinforces the classification of this tumor as a low-grade malignancy.
  • [MeSH-major] Adenocarcinoma, Clear Cell / secondary. Lung Neoplasms / secondary. Lymphatic Metastasis / pathology. Neoplasms, Second Primary / secondary. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Aged. Disease-Free Survival. Fatal Outcome. Humans. Male. Middle Aged. Neoplasm Metastasis / pathology. Salivary Glands, Minor / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19464657.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Hu YH, Li J: [Clear cell carcinoma of salivary gland: a clinicopathologic study of 10 cases]. Zhonghua Kou Qiang Yi Xue Za Zhi; 2005 Jan;40(1):54-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clear cell carcinoma of salivary gland: a clinicopathologic study of 10 cases].
  • OBJECTIVE: To analyze the clinicopathologic features of clear cell carcinoma of salivary gland.
  • Microscopically, the tumors were predominantly composed of trabeculae, cords, nests, solid sheets of clear cells and a few eosinophilic cells, and the two kinds of tumor cells were surrounded by hyalinized stroma.
  • There was no evidence of recurrence of disease or metastasis in eight followed-up patients.
  • CONCLUSIONS: CCC is a distinctive low grade malignant salivary gland neoplasm, arising mainly in the minor salivary glands, and it may originate from intercalated-duct reserve cells.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Salivary Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15774154.001).
  • [ISSN] 1002-0098
  • [Journal-full-title] Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology
  • [ISO-abbreviation] Zhonghua Kou Qiang Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


89. Skírnisdóttir I, Seidal T, Karlsson MG, Sorbe B: Clinical and biological characteristics of clear cell carcinomas of the ovary in FIGO stages I-II. Int J Oncol; 2005 Jan;26(1):177-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and biological characteristics of clear cell carcinomas of the ovary in FIGO stages I-II.
  • Clear cell carcinoma of the ovary is considered to be a specific subtype among the epithelial ovarian malignancies.
  • To characterize clear cell carcinomas in early FIGO stages (I-II) with regard to clinical and biological properties, a retrospective study was performed to compare these tumors with other histological subtypes.
  • From a complete series of 226 patients with epithelial ovarian carcinomas in FIGO stages I-II, 28 patients with clear cell carcinomas were selected and the clinical and biological characteristics of these tumors were compared with the remaining non-clear cell carcinomas.
  • Clear cell carcinomas stained negative for p53 significantly more often than other histological subtypes.
  • Positive EGFR staining was seen more frequently in serous carcinomas than in the clear cell carcinomas.
  • Aneuploid DNA status was seen more frequently in clear cell carcinomas than in other histological subtypes and tetraploid tumors made up 50% of the non-diploid tumors.
  • Clear cell tumors were frequently (64%) found in FIGO stages IC and IIC and this was more common than for non-clear cell tumors.
  • No difference was found in the rate of tumor recurrences or survival for patients with clear cell and non-clear cell carcinomas.
  • Clear cell carcinomas of the ovary should be regarded as a separate entity among the epithelial ovarian carcinomas and they differ with regard to both clinical and biological characteristics when compared with non-clear cell tumors.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Ovarian Neoplasms / diagnosis


90. Dalton SR, LeBoit PE: Squamous cell carcinoma with clear cells: how often is there evidence of tricholemmal differentiation? Am J Dermatopathol; 2008 Aug;30(4):333-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma with clear cells: how often is there evidence of tricholemmal differentiation?
  • Clear-cell carcinoma of the skin was described by Kuo in 1980 as a cutaneous tumor composed of clear cells that lacked cytoplasmic glycogen or evidence of tricholemmal keratinization.
  • Tricholemmal carcinoma (TC) is conventionally considered to be a neoplasm derived from adnexal keratinocytes with glycogenated clear cells and evidence of outer root sheath or tricholemmal differentiation.
  • The existence of TC has been questioned as it has been argued that without clear immunohistochemical evidence of outer root sheath differentiation, TC cannot be distinguished from clear-cell carcinoma of the skin.
  • Our laboratory has not routinely stained the cases that appear to be carcinomas with clear keratinocytes to determine if glycogen is present and has not made the diagnosis of TC.
  • We sought to test whether the presence of glycogen, light microscopic features said to be typical of TC, or immunohistochemical findings would delineate a group of "true" TC among the cases that we have been recording as squamous cell carcinomas with clear cells (SCC-C).
  • Overall, the carcinomas showed a spectrum of the above aggregated criteria ranging from 0 to 5.
  • The glycogen-free clear-cell carcinoma described by Kuo seems uncommon in our patient population.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Neoplasms, Adnexal and Skin Appendage / pathology. Skin Neoplasms / pathology


91. Petignat P, Usel M, Gauthier P, Popowski Y, Pelte MF, Bouchardy C, Verkooijen HM: Outcome of uterine clear cell carcinomas compared to endometrioid carcinomas and poorly-differentiated endometrioid carcinomas. Eur J Gynaecol Oncol; 2008;29(1):57-60
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of uterine clear cell carcinomas compared to endometrioid carcinomas and poorly-differentiated endometrioid carcinomas.
  • OBJECTIVES: Our aim was to compare the survival between patients with clear cell carcinoma (CC) and patients with endometrioid carcinoma (EC).
  • We excluded those with papillary serous endometrial carcinoma and uterine sarcomas.
  • RESULTS: CC patients presented with a more advanced stage at diagnosis than EC patients (p = 0.002).
  • Compared to women with EC, women with CC had a significantly greater risk of dying from their disease (hazard ratio [HR] 2.9, 95% confidence interval (95% CI) 1.7-4.9).
  • [MeSH-major] Adenocarcinoma, Clear Cell / surgery. Carcinoma, Endometrioid / surgery. Registries. Uterine Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18386465.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


92. Tan DS, Lambros MB, Rayter S, Natrajan R, Vatcheva R, Gao Q, Marchiò C, Geyer FC, Savage K, Parry S, Fenwick K, Tamber N, Mackay A, Dexter T, Jameson C, McCluggage WG, Williams A, Graham A, Faratian D, El-Bahrawy M, Paige AJ, Gabra H, Gore ME, Zvelebil M, Lord CJ, Kaye SB, Ashworth A, Reis-Filho JS: PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clin Cancer Res; 2009 Apr 1;15(7):2269-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PPM1D is a potential therapeutic target in ovarian clear cell carcinomas.
  • PURPOSE: To identify therapeutic targets in ovarian clear cell carcinomas, a chemoresistant and aggressive type of ovarian cancer.
  • EXPERIMENTAL DESIGN: Twelve ovarian clear cell carcinoma cell lines were subjected to tiling path microarray comparative genomic hybridization and genome-wide expression profiling analysis.
  • The prevalence of PPM1D amplification and mRNA expression was determined using chromogenic in situ hybridization and quantitative real-time reverse transcription-PCR in a cohort of pure ovarian clear cell carcinomas and on an independent series of unselected epithelial ovarian cancers.
  • PPM1D had significantly higher levels of mRNA expression in ovarian clear cell carcinoma cell lines harboring gains/amplifications of 17q23.2.
  • PPM1D inhibition revealed that PPM1D expression and phosphatase activity are selectively required for the survival of ovarian clear cell carcinoma cell lines with 17q23.2 amplification.
  • PPM1D amplification was significantly associated with ovarian clear cell carcinoma histology (P = 0.0003) and found in 10% of primary ovarian clear cell carcinomas.
  • PPM1D expression levels were significantly correlated with PPM1D gene amplification in primary ovarian clear cell carcinomas.
  • CONCLUSION: Our data provide strong circumstantial evidence that PPM1D is a potential therapeutic target for a subgroup of ovarian clear cell carcinomas.
  • [MeSH-major] Adenocarcinoma, Clear Cell / genetics. Cyclopentanes / pharmacology. Gene Amplification. Ovarian Neoplasms / genetics. Phosphoprotein Phosphatases / genetics. Thiophenes / pharmacology
  • [MeSH-minor] Cell Line, Tumor. Chromosome Aberrations. Chromosomes, Human, Pair 17. Comparative Genomic Hybridization. Enzyme Inhibitors / pharmacology. Female. Gene Expression Profiling. Genes, p53. Humans. Mutation. RNA Interference. p38 Mitogen-Activated Protein Kinases / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19293255.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCT007093; 0 / Cyclopentanes; 0 / Enzyme Inhibitors; 0 / Thiophenes; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; EC 3.1.3.16 / Phosphoprotein Phosphatases; EC 3.1.3.16 / protein phosphatase 2C
  •  go-up   go-down


93. Loos M, Bergmann F, Bauer A, Hoheisel JD, Esposito I, Kleeff J, Schirmacher P, Büchler MW, Klöppel G, Friess H: Solid type clear cell carcinoma of the pancreas: differential diagnosis of an unusual case and review of the literature. Virchows Arch; 2007 Jun;450(6):719-26
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid type clear cell carcinoma of the pancreas: differential diagnosis of an unusual case and review of the literature.
  • It was found to be a solid infiltrating carcinoma with abundant clear cells.
  • DNA microarray analysis revealed a transcription profile clearly differing from that of normal pancreatic tissue and pancreatic ductal adenocarcinoma.
  • Despite metastatic behavior, the tumor displayed a more favorable course than conventional pancreatic ductal adenocarcinoma.
  • We suggest that this tumor be called solid type clear cell carcinoma of the pancreas.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Gene Expression Profiling. Humans. Immunohistochemistry. Keratins / metabolism. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Microarray Analysis. Middle Aged. Mucin-1 / metabolism. Oligonucleotide Array Sequence Analysis. Reverse Transcriptase Polymerase Chain Reaction. S100 Proteins / metabolism. Tomography, Spiral Computed. Vimentin / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17453235.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / MUC1 protein, human; 0 / Mucin-1; 0 / S100 Proteins; 0 / Vimentin; 68238-35-7 / Keratins
  • [Number-of-references] 39
  •  go-up   go-down


94. Catasus L, D'Angelo E, Pons C, Espinosa I, Prat J: Expression profiling of 22 genes involved in the PI3K-AKT pathway identifies two subgroups of high-grade endometrial carcinomas with different molecular alterations. Mod Pathol; 2010 May;23(5):694-702
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profiling of 22 genes involved in the PI3K-AKT pathway identifies two subgroups of high-grade endometrial carcinomas with different molecular alterations.
  • Previously, we showed that PIK3CA and p53 alterations in uterine endometrial carcinomas correlate with poor prognosis.
  • The purpose of this study was to analyze alterations of this pathway in endometrial carcinomas and correlate them with the most common genetic abnormalities.
  • Expression profiling of 22 genes involved in PI3K-AKT signaling pathway was analyzed in 38 endometrial carcinomas using TaqMan low-density array (TLDA) analysis.
  • Unsupervised clustering divided the high-grade endometrial carcinomas into two clusters.
  • Almost all non-endometrioid adenocarcinomas (serous and clear cell adenocarcinomas) were segregated into this cluster.
  • Low-grade endometrial carcinomas clustered in a third subgroup characterized by high frequency of PTEN mutations (10/17; 59%) and microsatellite instability (6/17; 35%).
  • Our results show that gene expression profile differences in the PI3K-AKT signaling pathway identify two subgroups of high-grade endometrial carcinomas with different molecular alterations (PI3K-AKT pathway vs p53 alterations) that may have distinct roles in endometrial carcinogenesis.
  • [MeSH-major] Carcinoma / genetics. Endometrial Neoplasms / genetics. Phosphatidylinositol 3-Kinases / genetics. Proto-Oncogene Proteins c-akt / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20173732.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


95. Takano M, Kikuchi Y, Yaegashi N, Kuzuya K, Ueki M, Tsuda H, Suzuki M, Kigawa J, Takeuchi S, Tsuda H, Moriya T, Sugiyama T: Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer; 2006 May 22;94(10):1369-74
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging.
  • A retrospective analysis was performed to evaluate the clinical characteristics and prognostic factors in the patients with clear cell carcinoma (CCC) of the ovary.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1989 Jan;32(1):65-71 [2642454.001]
  • [Cites] J Surg Oncol. 1984 Dec;27(4):289-97 [6503304.001]
  • [Cites] Gynecol Oncol. 1989 Nov;35(2):199-203 [2807010.001]
  • [Cites] Gynecol Oncol. 1993 May;49(2):250-4 [8504995.001]
  • [Cites] Gynecol Oncol. 1998 Aug;70(2):255-8 [9740700.001]
  • [Cites] Cancer. 1998 Oct 15;83(8):1555-60 [9781949.001]
  • [Cites] Ann Acad Med Singapore. 1998 Sep;27(5):650-6 [9919334.001]
  • [Cites] Gynecol Oncol. 1999 May;73(2):237-41 [10329040.001]
  • [Cites] Int J Cancer. 2005 Mar 1;113(6):977-90 [15505879.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6880-8 [16203778.001]
  • [Cites] J Natl Cancer Inst. 2005 Oct 5;97(19):1407-27 [16204691.001]
  • [Cites] Gynecol Oncol. 2005 Nov;99(2):427-31 [16112718.001]
  • [Cites] Jpn J Clin Oncol. 1999 Sep;29(9):434-7 [10563197.001]
  • [Cites] Oncol Rep. 2000 Mar-Apr;7(2):327-31 [10671681.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2584-9 [10861437.001]
  • [Cites] Gynecol Oncol. 2000 Nov;79(2):251-5 [11063653.001]
  • [Cites] Gynecol Oncol. 2001 Jan;80(1):56-61 [11136570.001]
  • [Cites] Jpn J Cancer Res. 2002 Jun;93(6):723-8 [12079522.001]
  • [Cites] Obstet Gynecol. 2002 Aug;100(2):281-7 [12151151.001]
  • [Cites] J Natl Cancer Inst. 2003 Jan 15;95(2):113-25 [12529344.001]
  • [Cites] Gynecol Oncol. 2003 Mar;88(3):394-9 [12648592.001]
  • [Cites] Oncology. 2003;65(1):29-36 [12837980.001]
  • [Cites] J Am Coll Surg. 2003 Aug;197(2):198-205 [12892797.001]
  • [Cites] Am J Pathol. 2003 Dec;163(6):2503-12 [14633622.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):147-59 [15043303.001]
  • [Cites] Gynecol Oncol. 2004 Jul;94(1):161-6 [15262135.001]
  • [Cites] Gynecol Oncol. 2004 Jul;94(1):197-203 [15262142.001]
  • [Cites] Gynecol Oncol. 1989 Mar;32(3):342-9 [2920955.001]
  • (PMID = 16641903.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2361284
  •  go-up   go-down


96. Cao D, Guo S, Allan RW, Molberg KH, Peng Y: SALL4 is a novel sensitive and specific marker of ovarian primitive germ cell tumors and is particularly useful in distinguishing yolk sac tumor from clear cell carcinoma. Am J Surg Pathol; 2009 Jun;33(6):894-904
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SALL4 is a novel sensitive and specific marker of ovarian primitive germ cell tumors and is particularly useful in distinguishing yolk sac tumor from clear cell carcinoma.
  • Ovarian primitive germ cell tumors (GCTs) are uncommon tumors and sometimes pose diagnostic challenges.
  • Among them, yolk sac tumor (YST) poses the greatest diagnostic difficulty and can be mistaken for clear cell carcinoma (CCC).
  • Here by immunohistochemistry, we investigated a novel marker SALL4 in 98 GCTs (29 YSTs, 18 dysgerminomas, 6 gonadoblastomas, 6 embryonal carcinomas, 15 immature and 12 mature teratomas, 7 carcinoid tumors, 3 strumal carcinoids, and 2 struma ovarii) with particular interest of exploring SALL4 to distinguish YST from CCC.
  • We found that SALL4 is strongly positive in more than 90% tumor cells in all YSTs, dysgerminomas, gonadoblastomas, and embryonal carcinomas.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Endodermal Sinus Tumor / diagnosis. Ovarian Neoplasms / diagnosis. Transcription Factors / biosynthesis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Neoplasms, Germ Cell and Embryonal / diagnosis. Neoplasms, Germ Cell and Embryonal / metabolism. Sensitivity and Specificity


97. Adley BP, Gleason KJ, Yang XJ, Stack MS: Expression of membrane type 1 matrix metalloproteinase (MMP-14) in epithelial ovarian cancer: high level expression in clear cell carcinoma. Gynecol Oncol; 2009 Feb;112(2):319-24
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of membrane type 1 matrix metalloproteinase (MMP-14) in epithelial ovarian cancer: high level expression in clear cell carcinoma.
  • OBJECTIVE: Clear cell carcinomas of the ovary constitute approximately 5% of all ovarian neoplasms and have a distinct gene expression profile relative to other ovarian carcinoma histotypes.
  • Matrix metalloproteinases (MMPs) play a role in intraperitoneal metastasis through breakdown of cell-cell and cell-matrix barriers, enabling anchoring of secondary lesions and promoting proliferation in a geometrically constrained matrix environment.
  • The objective of this study was to evaluate MMP expression in ovarian clear cell carcinoma.
  • METHODS: Immunohistochemistry was used to evaluate expression of membrane type 1 MMP (MMP-14), MMP-2 and MMP-9 in a panel of ovarian tumors.
  • Western blotting and gelatin zymography were used to examine MMP-14 expression and activity in the clear cell carcinoma cell line ES2.
  • RESULTS: High level expression of MMP-14 and MMP-2 were observed in ovarian clear cell carcinoma relative to other histotypes (94-95% strong positive).
  • CONCLUSIONS: The high level expression of MMP-14 together with in vitro functional analyses suggest that MMP-14 may contribute to both the proliferative capacity and the enhanced parenchymal metastasis of ovarian clear cell carcinoma.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 2003 May 8;194(1):1-11 [12706853.001]
  • [Cites] J Biol Chem. 2002 Oct 11;277(41):39005-14 [12145314.001]
  • [Cites] Mol Hum Reprod. 2003 Oct;9(10):569-75 [12970394.001]
  • [Cites] Mol Biol Cell. 2003 Nov;14(11):4376-86 [12960427.001]
  • [Cites] J Biol Chem. 2004 Feb 27;279(9):8278-89 [14670950.001]
  • [Cites] Am J Obstet Gynecol. 2004 Apr;190(4):899-909 [15118611.001]
  • [Cites] J Biol Chem. 2004 Sep 10;279(37):39042-50 [15247230.001]
  • [Cites] J Pathol. 1983 Mar;139(3):337-47 [6834177.001]
  • [Cites] Gynecol Oncol. 1989 Jan;32(1):65-71 [2642454.001]
  • [Cites] Kidney Int. 1990 Jun;37(6):1563-70 [2362409.001]
  • [Cites] Cancer Res. 1993 Oct 15;53(20):5028-32 [8402695.001]
  • [Cites] Int J Gynecol Pathol. 1996 Apr;15(2):102-9 [8786198.001]
  • [Cites] Anticancer Res. 1995 Nov-Dec;15(6B):2799-804 [8669868.001]
  • [Cites] Hum Pathol. 1998 Feb;29(2):155-65 [9490275.001]
  • [Cites] Gynecol Oncol. 1998 Aug;70(2):255-8 [9740700.001]
  • [Cites] Eur J Gynaecol Oncol. 1998;19(5):438-40 [9863906.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1635-41 [10197640.001]
  • [Cites] Gynecol Oncol. 1999 Oct;75(1):91-8 [10502432.001]
  • [Cites] Cell. 1999 Oct 1;99(1):81-92 [10520996.001]
  • [Cites] J Cell Biol. 2004 Nov 22;167(4):769-81 [15557125.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6422-30 [16166416.001]
  • [Cites] J Cell Physiol. 2006 Jan;206(1):1-8 [15920734.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1707-14 [16551853.001]
  • [Cites] Br J Cancer. 2006 May 22;94(10):1369-74 [16641903.001]
  • [Cites] Head Neck. 2006 Jul;28(7):639-48 [16470875.001]
  • [Cites] J Biol Chem. 2007 Feb 16;282(7):4924-31 [17158885.001]
  • [Cites] Gynecol Oncol. 2007 May;105(2):404-8 [17292461.001]
  • [Cites] Br J Cancer. 2007 Aug 6;97(3):358-67 [17609667.001]
  • [Cites] Tumour Biol. 2007;28(5):280-9 [17962725.001]
  • [Cites] Semin Cell Dev Biol. 2008 Feb;19(1):24-33 [17702616.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2584-9 [10861437.001]
  • [Cites] Int J Oncol. 2000 Oct;17(4):673-81 [10995877.001]
  • [Cites] Hum Pathol. 2001 Feb;32(2):163-8 [11230703.001]
  • [Cites] Am J Clin Pathol. 2001 Apr;115(4):517-24 [11293899.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3194-9 [11306508.001]
  • [Cites] J Biol Chem. 2001 Jul 6;276(27):24833-42 [11331272.001]
  • [Cites] Cancer Treat Res. 2002;107:185-211 [11775450.001]
  • [Cites] Mol Cell Endocrinol. 2002 Feb 22;187(1-2):39-45 [11988310.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4722-9 [12183431.001]
  • [Cites] Cell. 2003 Jul 11;114(1):33-45 [12859896.001]
  • (PMID = 18976802.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA086984-07; United States / NCI NIH HHS / CA / R01 CA086984-09; United States / NCI NIH HHS / CA / R01 CA086984; United States / NCI NIH HHS / CA / R01 CA109545-01A2; United States / NCI NIH HHS / CA / R01CA86984; United States / NCI NIH HHS / CA / CA109545-02; United States / NCI NIH HHS / CA / R01 CA109545-03; United States / NCI NIH HHS / CA / CA086984-08; United States / NCI NIH HHS / CA / CA109545-01A2; United States / NCI NIH HHS / CA / R01 CA086984-07; United States / NCI NIH HHS / CA / R01 CA086984-06; United States / NCI NIH HHS / CA / CA109545-03; United States / NCI NIH HHS / CA / R01 CA109545-02; United States / NCI NIH HHS / CA / R01 CA109545; United States / NCI NIH HHS / CA / CA086984-06; United States / NCI NIH HHS / CA / R01 CA086984-08; United States / NCI NIH HHS / CA / R01CA109545; United States / NCI NIH HHS / CA / CA086984-09
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.24.24 / MMP2 protein, human; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.80 / MMP14 protein, human; EC 3.4.24.80 / Matrix Metalloproteinase 14
  • [Other-IDs] NLM/ NIHMS96743; NLM/ PMC2663392
  •  go-up   go-down


98. Kwon JS, Abrams J, Sugimoto A, Carey MS: Is adjuvant therapy necessary for stage IA and IB uterine papillary serous carcinoma and clear cell carcinoma after surgical staging? Int J Gynecol Cancer; 2008 Jul-Aug;18(4):820-4
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is adjuvant therapy necessary for stage IA and IB uterine papillary serous carcinoma and clear cell carcinoma after surgical staging?
  • Adjuvant therapy of early-stage uterine papillary serous carcinoma (UPSC) and clear cell carcinoma (CCC) is controversial.
  • Primary outcome measure was 2-year disease-free survival.
  • Nine had stage IA and 13 had stage IB disease.
  • Two-year disease-free survival was 95%.
  • [MeSH-major] Adenocarcinoma, Clear Cell / radiotherapy. Cystadenocarcinoma, Papillary / radiotherapy. Cystadenocarcinoma, Serous / radiotherapy. Neoplasm Staging / methods. Radiotherapy, Adjuvant / methods. Uterine Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17892450.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Fakiris AJ, Henderson M, Lo SS, Look KY, Cardenes HR: Intraperitoneal radioactive phosphorus (32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: the Indiana University experience. Brachytherapy; 2010 Jan-Mar;9(1):61-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraperitoneal radioactive phosphorus (32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: the Indiana University experience.
  • PURPOSE: To evaluate the outcomes of surgically staged patients with Stage I-IIIA uterine papillary serous carcinoma (UPSC) and clear cell carcinoma (CCC) of the uterus treated at Indiana University with intraperitoneal (32)P and vaginal brachytherapy.
  • All patients underwent comprehensive surgical staging with negative pelvic and para-aortic lymph nodes and no gross residual disease.
  • There were 4 patients with recurrent disease: 2 initially relapsed intraperitoneally, 1 in the distal vagina, and 1 had a scar recurrence.
  • Three patients have died of the disease.
  • For all 27 patients, the 3-year overall survival, cause-specific survival, and disease-free survival were 84.2%, 90.7%, and 74.4%, respectively.
  • [MeSH-major] Adenocarcinoma, Clear Cell / radiotherapy. Brachytherapy / methods. Carcinoma, Papillary / radiotherapy. Phosphorus Radioisotopes / administration & dosage. Uterine Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20129252.001).
  • [ISSN] 1873-1449
  • [Journal-full-title] Brachytherapy
  • [ISO-abbreviation] Brachytherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Phosphorus Radioisotopes; 0 / Radiopharmaceuticals
  •  go-up   go-down


100. Lee L, Garrett L, Lee H, Oliva E, Horowitz N, Duska LR: Association of clear cell carcinoma of the endometrium with a high rate of venous thromboembolism. J Reprod Med; 2009 Mar;54(3):133-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of clear cell carcinoma of the endometrium with a high rate of venous thromboembolism.
  • OBJECTIVE: To document the rate of clinically significant venous thromboembolism (VTE) in patients with clear cell carcinoma of the endometrium (CCC-E).
  • Controls with high grade endometrial cancers were matched for stage, age and date of diagnosis.
  • More VTE occurred in patients with stage III/IV disease (n = 16) than those with early stage (n = 2).
  • VTE in patients with CCC-E occurred at presentation or with disease recurrence rather than in the postoperative period (8 vs. 1).
  • [MeSH-major] Adenocarcinoma, Clear Cell / epidemiology. Endometrial Neoplasms / epidemiology. Fibrinolytic Agents / therapeutic use. Venous Thromboembolism / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19370896.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fibrinolytic Agents
  •  go-up   go-down






Advertisement